

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

Glaucoma and Ten-Year Mortality: The Liwan Eye Study

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-040795
Article Type:	Original research
Date Submitted by the Author:	29-May-2020
Complete List of Authors:	Wang, Langhua; Zhongshan ophthalmic center, Sun Yat-sen University Zhu, Zhuoting; Sun Yat-sen University, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center Huang, Wenyong; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China Scheetz, Jane; Centre for Eye Research Australia Ltd He, Mingguang; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University,
Keywords:	Glaucoma < OPHTHALMOLOGY, EPIDEMIOLOGY, PUBLIC HEALTH, OPHTHALMOLOGY





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Glaucoma and Ten-Year Mortality: The Liwan Eye Study

Running tilt: Glaucoma and mortality

Research question: The association between glaucoma and 10-year

mortality in an adult population in China

Study design: Population-based cohort study

Authors

Lanhua Wang MD, PhD1*

Zhuoting Zhu MD, PhD1*

Wenyong Huang MD, PhD¹

Jane Scheetz, PhD²

Mingguang He MD, PhD¹

*These authors contributed equally to this study.

Institutions

 State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China

eziez

 Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia

Financial support: Supported by the Fundamental Research Funds of the State Key Laboratory of Ophthalmology, National Natural Science Foundation of China (81420108008 and 81570843H1204), and Science and Technology Planning Project of Guangdong Province, China 2013B20400003.

Conflict of Interest: The authors have no financial or other conflicts of interest concerning this study.

Data availability: All data relevant to the study are included in the article or uploaded as supplementary information.

Correspondence:

Prof Mingguang He

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center,

Licz

Guangzhou 510060, People's Republic of China

Email: mingguanghe@gmail.com

Word count: Abstract:259; Whole paper: 2994.

Tables: 4 Figure: 0

Abstract

Objectives: To investigate the association between glaucoma and 10-year mortality in an adult population in China.

Design: Population-based cohort study.

Setting: The Guangzhou Liwan Eye Study.

Participants: A total of 1405 participants aged 50 years and above at baseline examination were invited to attend the 5- and 10-year follow-up examinations.

Primary and secondary outcome measures: The International Society of Geographic and Epidemiologic Ophthalmology criteria was used to define glaucoma. Presenting visual impairment (PVI) was defined as a presenting visual acuity of 20/40 or worse in the better-seeing eye. The 10-year mortality rates were compared using the log-rank test and Cox proportional hazards regression models.

Results: A total of 1372(97.7%) participants with available gonioscopic data were included in the present analysis. Of them, 136(9.9%), 33(2.4%) and 21(1.5%) participants had primary angle closure suspect (PACS), primary angle closure (PAC) and primary angle closure glaucoma (PACG) and 29(2.1%) participants had primary open angle glaucoma (POAG). After 10 years, 306 (22.3%) participants had died. The 10-year mortality were significantly associated with PACG(HR,2.15,95%CI:1.14-4.04) but not associated with PACS and POAG when age and gender was adjusted for. This association was no longer statistically significant when more co-variables, such as income, educational attainment, BMI, PVI, history of diabetes and hypertension, were adjusted for. Larger vertical cup-to-disc ratio (VCDR>0.30) was only significant risk factor in multivariate analysis (HR,1.60;95%CI,1.11-2.33).

Conclusions: PACG was significantly associated with higher long-term mortality but this association was likely confounded by other systemic risk factors. VCDR>0.3 was the only independent predictor, implying that VCDR might be a marker of ageing and frailty.

Patient and Public Involvement Statement: There were no patients and public involved in the design and process of this study.

Key words: Glaucoma; Mortality; China; Cox proportional hazards regression model

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Strengths and limitations of this study

1. The present study was a population-based cohort study with standardized study protocol

The use of the International Society of Geographic and Epidemiologic
 Ophthalmology criteria to define glaucoma

inclu, ral importan, 3. Study limitations include the following: 1) the small number of patients with glaucoma;2) several important confounding factors, such as smoking were not available.

Introduction

Glaucoma, one of the leading causes of irreversible visual impairment (VI) and blindness, affects approximately 64.3 million people worldwide.¹ It has been estimated that the number of people diagnosed with glaucoma in China was 13.1 million in 2015, with more than half of those diagnosed with primary angle closure glaucoma.² As the population continues to age, the number of people with glaucoma in China is expected to reach 15.2 million by 2050.²

In addition to its impact on vision and quality of life, some studies have indicated that patients with glaucoma have higher rates of mortality,³⁻⁶ while others have found no association,⁷⁻¹⁸ leading to controversies regarding the risk of premature mortality of patients with glaucoma. Similarly, inconsistent evidence has been observed for the association between level of intraocular pressure (IOP), a well-established functional risk factor for glaucoma, and survival.^{14, 17,} ¹⁸ The relationship between mortality and vertical cup-to-disc ratio (VCDR), a robust structural indicator of glaucomatous loss of the neuroretinal rim, has been exclusively investigated in the Andhra Pradesh Eye Disease Study (APEDS), implying that nerve fiber loss may be a marker of ageing and frailty.⁷ Of note, previous studies, mainly in white and black populations, investigated the relationship between primary open angle glaucoma (POAG), elevated IOP and long-term survival.^{8-10, 12, 14, 15, 18, 19} Few studies have been conducted in Asian populations.^{3, 4, 7, 11, 13, 16} Furthermore, dominant subtypes, clinical presentations and the underlying pathogenesis of glaucoma vary in Asian populations compared to white and black populations.^{20, 21} A better understanding of the relationship between different subtypes of glaucoma (POAG and primary angle closure disease (PACD)), level of IOP, VCDR and risk of mortality may provide insights into the potential mechanisms and clinical management of glaucoma.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Therefore, the aim of this study was to explore the relationship between different types of glaucoma, level of IOP, VCDR and 10-year mortality in an adult population in southern urban China.

BMJ Open

Methods

Study Population

A detailed description of the methodology utilized in the Liwan Eye Study has been described previously.²² Briefly, the Liwan Eye Study was a populationbased cohort study initiated in 2003 with a five-year follow-up from 2008 to 2009 and a ten-year follow-up in 2013 following an identical protocol. At baseline, 75.4% (1405 of 1864) of eligible participants underwent a comprehensive eye examination and a questionnaire regarding income, education, and medical history. All participants in the baseline study were invited to take part in the five- and ten-year follow-up examinations. A total of 924 participants (75.0% of survivors, 79.1% of eligible participants) returned for the five-year examination and 791 participants (73.8% of survivors, 86.2% of eligible participants) for ten-year examination.

Ethical approval for the study was obtained from the Zhongshan University Ethics Review Board, and the Research Governance Committee of Moorfields Eye Hospital, London. The study was conducted in accordance with the tenets of the World Medical Association's Declaration of Helsinki. Written informed consent was obtained from all participants.

Study procedure

All participants had their presenting visual acuity (PVA) with habitual refractive $\frac{7}{7}$

Page 9 of 29

BMJ Open

correction tested using an Early Treatment Diabetic Retinopathy Study (ETDRS) vision chart. Best-corrected visual acuity (BCVA) was measured for those with PVA \leq 20/40 in either eye. Presenting visual impairment (PVI) was defined as PVA less than 20/40 in the better-seeing eye. The IOP was measured before mydriasis by a handheld tonometer (Tonopen; Mentor, Norwell, Massachusetts, USA) with three consecutive measurements achieving standard error <5%. Central cornea thickness (CCT) was evaluated using an ultrasound pachymetry (Echoscan US1800; Nidek,Corp). Height and weight were measured without shoes, using a standard calibrated scale. Body mass index (BMI) was calculated as the weight in kilograms divided by the square of the height in centimeters and was divided into three group: underweight (BMI <18.5 kg/m²), normal to overweight (18.5 to30 kg/m²), or obesity (BMI \geq 30.0 kg/m²). Diabetes mellitus (DM) and hypertension were based on self-reported history of a diagnosis and/or previous medication use.

Slit-lamp examination (TopconSL-8Z, Tokyo, Japan) with a 78-diopter lens was used to identify abnormalities of the anterior segment and posterior segment by an experienced ophthalmologist (MH). Detailed information of the gonioscopic examination in the Liwan Eye Study has been described previously.²² Briefly, all participants underwent slit lamp based static and dynamic gonioscopy with a Goldmann-type, one-mirror lens (Haag Streit, Bern, Switzerland) at 25x magnification by the same experienced specialisttrained ophthalmologist (MH). Narrow angle and open angle were stratified by status of the iris insertion which was recorded using five categories by the Shaffer system. ²³According to the International Society of Geographical and Epidemiological Ophthalmology (ISGEO) classification, primary angle closure suspect (PACS) was defined as simply an angle in which ≥270°of the pigmented trabecular meshwork cannot be seen without evidence of Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

trabecular obstruction and glaucomatous damage. Primary angle closure (PAC) was defined as eyes with PACS and features of peripheral anterior synechiae, elevated IOP, iris wholing, or excessive pigment deposition on the trabecular surface, but no evidence of glaucomatous damage. Primary angle closure glaucoma (PACG) was defined as eyes with PAC and evidence of glaucomatous damage. Participants with PACS, PAC or PACG were grouped as PACD.

The optic disc was assessed using a 78-D lens at 16x magnification. The VCDR was used as the key indicator of structural glaucomatous change. Visual field (VF) assessment was performed in those with a VCDR of \geq 0.7 in either eye, VCDR asymmetry \geq 0.2 or IOP of \geq 21 mm Hg on a subsequent day. The definition of glaucoma was based on three levels of evidence using ISGEO criteria, and the division of POAG and PACG was based on the gonioscopic results of narrow angle or open angle. If glaucoma status or VCDR were available for both eyes, the eye with the more severe status or larger VCDR value was used in the analysis.

Detailed data from the Chinese Centre for Disease Control and Prevention (CDC) were used to confirm the mortality of participants during the 10-year follow-up period. After providing the CDC with a list of names, age, year of birth, gender and last known address for the participants that were suspected of having passed away, researchers at the CDC provided a corresponding list of "matched" deaths that included a list of time of death and causes of death for individuals who matched. The CDC recorded causes of death documented on death certificates using the International Classification of Diseases, Ninth Revision.

Statistical analysis

All statistical analyses were performed using Stata (ver. 10.0; Stata Corp., College Station, TX). The student's t-test was used to compare continuous variables, while Pearson chi squire or Fisher's exact test were used for the comparison of categorical data. Survival times were calculated for each participant from the date of baseline examinations through to the date of death or April 30, 2014. Univariate and multivariate Cox proportional hazard regression models were used to test the associations between incident mortality and baseline PACS, PAC, PACG, POAG, IOP and VCDR after adjusting for baseline characteristics of age, gender, education level, family income, history of diabetes and hypertension and PVI. Analysis of IOP and VCDR were based on both continuous level and categorical group. IOP was divided into three categorical groups: 10-21mmHg (reference group), <10mmHg and >21 mmHg. The lowest quartile of VCDR (<0.3), the third quartile of VCDR in this population (<0.5) and VCDR of < 0.7 (the common criteria for glaucoma diagnosis) were used as the reference group to assess associations of different VCDR cut-offs with long-term survival. Hazard ratios (HR) and 95% CI were given. A proportional hazard test was used to check the assumption of cox proportional hazards model, and the log-rank test was used to compare different groups with respect to their survival distributions. A p value of < 0.05 was defined to indicate statistical significance.

Results

Of the 1405 participants at baseline, 33 did not have gonioscopic data and were therefore excluded, leaving 1372 available for analysis. Among the 1372 participants, the prevalence of PACS, PAC, PACG, and POAG was 9.9% (136 participants), 2.4% (33 participants), 1.5% (21 participants), and 2.1% (29

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

participants), respectively. Compared to the 1153 normal participants, those with PACD were more likely to be older (P<0.001), female (P=0.001), underweight (P<0.001), of a lower level of family income (P=0.005) and higher proportion of PVI (P<0.001). There were no statistically significant differences between groups in terms of level of education, hypertension, diabetes, CCT and IOP. Compared to the 1,153 normal participants, those with POAG tended to be older (P=0.003), male (P=0.003) and had a higher proportion of PVI (P=0.001) (Table 1).

By the end of April 2014 (median follow-up length: 9.38 years; range: 0.15-10.2), a total of 306 (22.8%) of the 1,372 participants passed away during the 10-year follow-up. Those who passed away tended to be older (P<0.001), male (P<0.001), had a lower level of educational attainment (P=0.001), lower family income (P<0.001), higher proportion of PVI (P<0.001), larger VCDR (P<0.001) and be underweight (P=0.009). The medical history of hypertension and diabetes, CCT and mean IOP value were similar between the two groups (Table 2).

Among the 1153 participants without PACD or POAG, 235 (20.4%, 95%CI=18.1, 22.8%) passed away during the 10-year follow up period. The 10-year mortality rate was significantly lower than those with PACS (31.6%, 95%CI= 23.9, 40.1%), PAC (30.3%, 95%CI= 15.6, 48.7%), PACG (47.6%, 95%CI=25.7, 70.2%), and POAG (27.6%, 95%CI= 12.7, 47.2%). The age and gender adjusted cox proportional hazards model showed that the presence of PACG (HR=2.15, 95% CI=1.14, 4.04), PACD (HR=1.46, 95% CI=1.10, 1.95) and a VCDR of more than 0.3 (HR=1.53, 95% CI=1.16, 2.01) were significantly associated with a higher risk of mortality. No association was

found between mortality and PACS, PAC, POAG and level of IOP. After adjusting for age, gender, education, income, history of diabetes and hypertension, BMI and PVI, the significant association between VCDR of more than 0.3 and poorer survival rate was still observed (HR=1.60, 95% CI=1.11, 2.33) (Table 3 and Table 4). We further analysed the associations of VCDR>0.5 and VCDR≥0.7 with 10 year mortality, and the results showed that both VCDR>0.5 (HR=1.37, 95% CI=1.06, 1.78) and VCDR≥0.7 (HR=1.62, 95% CI=1.18, 2.20) were strongly associated with mortality in the univariate analysis, whereas these associations disappeared after adjusting for confounders (all P>0.05, Supplement Table 1).

Discussion

In this population-based cohort study, we found a higher (ranging from 7.2% to 27.2%) crude mortality rate among patients with POAG or any form of PACD. However, this difference was not replicated after multivariate confounders were adjusted for. Level of IOP was not significantly associated with an increased risk of 10-year mortality in the multivariate model, while VCDR of more than 0.3 was an independent predictor of long-term poor survival.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Controversy still exists around the association between POAG and increased risk of mortality.^{3-10, 12, 14-16, 18, 19} Almost 50 years ago, Egge et al found a decreased 30-year survival rate for patients with glaucoma in Norway. This finding was more pronounced among men using acetazolamide.⁶ Results of the National Health Interview Survey (NHIS) 1986-1994 also supported the finding that glaucoma was related to an increased risk of all-cause and cardiovascular disease mortality among adults residing in the United States.⁵

BMJ Open

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

However, the glaucoma-mortality association in the NHIS is likely to have been subjected to recall bias (self-reported definition of glaucoma), misclassification error and underestimation of glaucoma cases. Furthermore, the diagnostic methods, definition and treatments of glaucoma have changed over the past five decades, thus making its findings less generalizable to today's glaucoma patients. More recent studies were in favor of the finding that POAG was not significantly associated with long-term survival.^{3, 4,7-10, 12, ^{14-16, 18} The non-significant relationship in these studies are in agreeance with our results. Differences in ethnicity, age distribution, study design, length of follow-up, definition of glaucoma, and confounding variables adjusted in the multivariate model may explain inconsistent results between studies. Alternatively, the small number of patients with POAG in the current study (n=29) may also explain the lack of association between POAG and 10-year mortality. However, a recent meta-analysis of observational studies¹⁷ also supported a non-significant relationship between POAG and risk of mortality.}

Few studies have explored the relationship between different types of PACD and mortality. The present study resulted in similar findings to those who previously investigated that the presence of PACD was not an independent risk factor for all-cause mortality.^{7, 11, 13, 16} Thus far, only 5-year data from the Beijing Eye Study has reported that the presence of PACG was related to an increased risk of mortality using multivariate analysis.^{3, 4} Interestingly, the 10year data from the Beijing Eye Study found that mortality was not significantly associated with PACG.¹⁶ Neither the Tanjong Pagar Study¹¹ or the Singapore Malay Eye Study (SiMES)¹³ found statistically reduced survival among those with glaucoma. In the current study, we found that PACG was significantly associated with 10-year mortality in the age and gender adjusted model, but this significant association disappeared in the multivariate model. The

BMJ Open

possible reason might be that PACG-mortality association was confounded by other systemic risk factors or relatively small study sample size.

The results of this study found a non-significant association between the level of IOP and 10-year mortality. Previous reports on the relationship between allcause mortality and elevated IOP have been inconsistent.^{7, 14, 18, 19} The excess all-cause mortality associated with ocular hypertension was found in the Barbados Eye Study and in the Framingham Study,¹⁸ while in the APEDS⁷ and in a Sweden study,¹⁴ no statistically significant association was found between elevated IOP and mortality risk. The APEDS was the only study to explore the association between VCDR and all-cause mortality. Consistent with the APEDS's finding that the increasing VCDR was a predictor of 10-year mortality,⁷ we also reported a significantly increased risk of mortality among participants with VCDR of more than 0.3. Considering that previous studies indicated that global retinal nerve fiber layer decreased significantly with ageing and larger VCDR,^{24, 25} one can speculate that the potential mechanism underlying the VCDR-mortality association may be caused by retinal nerve fiber layer thinning, a marker of ageing and frailty. Furthermore, the close relationship between neurodegenerative diseases (e.g., Alzheimer's disease and Parkinson's disease) and glaucoma, and the strong link between retinal nerve fiber layer thinning and brain pathology, again verified our speculation.²⁶⁻²⁹ Further studies with a larger study sample are needed to investigate the association between VCDR, retinal nerve fiber layer thickness and mortality. The non-significant association of long-term survival with VCDR>0.7, a common cut-off for glaucoma diagnosis, might be partly due to the small sample size in our study. Alternatively, we might speculate that only VCDR less than 0.3 (i.e., sufficient retinal nerve fibre layer) might be the threshold for better survival.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Even though the mechanisms underlying glaucoma/ocular hypertensionmortality association is still unclear, it had been speculated that increased risk of mortality among patients with glaucoma or ocular hypertension might be caused by IOP-lowering treatment. Egge found the glaucoma-mortality association was more pronounced among men using acetazolamide.⁶ The excess mortality linked to timolol maleate treatment for POAG found in the Barbados Eye Study¹⁸ was also parallel to the hypothesis of this study. In the BMES, a dose-dependent pattern was observed in the association between duration of timolol maleate use and the increased risk of cardiovascular disease mortality. In addition, previous studies verified the adverse effects of IOP-lowering treatments, including congestive heart failure, raised blood pressure and adverse respiratory effects.^{30, 31} However, the dose-dependent pattern observed in the BMES might be due to detection bias. Approximately 50-90% of glaucoma patients remain undiagnosed.^{7, 32} Participants in poorer health are more likely to access health care services and therefore have their glaucoma diagnosed and treated. The suggestion that detection bias is a cause of variable findings was further verified by the similar mortality rates between treated and untreated glaucoma patients in multicenter randomized glaucoma treatment trials (Early Manifest Glaucoma Trial and Ocular Hypertension Treatment Study) and the observational Rotterdam study (Rotterdam Study).³³⁻³⁵ Even these two studies concluded that the use of glaucoma medications was associated with a reduced risk of mortality.^{36, 37} Future investigations should assess this association further.

The strengths of the present study included the population-based study design, high participation rate, long-term follow-up, and a standardized definition of glaucoma. Of note, the present study was limited by the following points. Firstly, the small number of patients with glaucoma may explain the

BMJ Open

non-significant association between different types of glaucoma and mortality. Second, several important confounding factors, such as smoking were not available in the present study. Nevertheless, the additional adjustment for these important confounding factors may further attenuate the magnitude of statistical significance and again verify the robustness of our results. Third, the lack of data on the causes of death prevented the possibility of exploring the association between glaucoma and specific-cause mortality. Previous studies have reported a significant association between glaucoma and cardiovascular disease mortality.^{5, 38} Fourthly, the fact that only participants with suspect glaucoma (VCDR of >0.7 in either eve, VCDR asymmetry >0.2 or IOP of >21 mm Hg) underwent VF assessment may underestimate the prevalence of glaucoma because participants with early changes of VCDR due to glaucoma maybe missed. However, each participant underwent IOP measurements and the collection of information on previous history of glaucoma may lower this underestimation. Finally, we did not collect information on utilization of IOPlowering treatment. Further studies are required to investigate the relationship between IOP-lowering treatment and long-term survival.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

In conclusion, our findings suggest there are a higher level of crude mortality among patients with POAG, PACS or PAC. However, this difference was unable to be replicated after multivariate confounders were adjusted for. PACG was significantly associated with 10-year mortality in the age and gender adjusted model, but this significant association disappeared in the multivariate model. The level of IOP was not significantly associated with increased risk of 10-year mortality, while VCDR of more than 0.3 was an independent predictor of long-term survival. Further studies are needed to confirm these findings and to explore the association of different subtypes and treatments of glaucoma with long-term survival.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Acknowledgement:

Author Contributions: Study conception and design (LW, ZZ, MH); analysis and interpretation (LW, ZZ); writing of the article (LW, ZZ); critical revision of the article (JS, MH); data collection (LW, ZZ); administrative, technical or logistic support (JS, MH).

to perteries only

Reference

1. Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. *The British journal of ophthalmology* 2012;96:614-618.

2. Song P, Wang J, Bucan K, Theodoratou E, Rudan I, Chan KY. National and subnational prevalence and burden of glaucoma in China: A systematic analysis. *Journal of global health* 2017;7:020705.

3. Xu L, Wang YX, Jonas JB. Glaucoma and mortality in the Beijing Eye Study. *Eye* 2008;22:434-438.

4. Xu L, Wang YX, Wang J, Jonas JJ. Mortality and ocular diseases: the Beijing Eye Study. *Ophthalmology* 2009;116:732-738.

5. Lee DJ, Gomez-Marin O, Lam BL, Zheng DD. Glaucoma and survival: the National Health Interview Survey 1986-1994. *Ophthalmology* 2003;110:1476-1483.

6. Egge K, Zahl PH. Survival of glaucoma patients. *Acta ophthalmologica Scandinavica* 1999;77:397-401.

7. Khanna RC, Murthy GVS, Giridhar P, et al. Glaucoma-associated long-term mortality in a rural cohort from India: the Andhra Pradesh Eye Disease Study. *The British journal of ophthalmology* 2018;102:1477-1482.

8. Sundqvist J, Ekstrom C. Open-angle glaucoma and mortality: A long-term follow-up study. *Acta ophthalmologica* 2018;96:e1038-e1039.

9. Borger PH, van Leeuwen R, Hulsman CA, et al. Is there a direct association between age-related eye diseases and mortality? The Rotterdam Study. *Ophthalmology* 2003;110:1292-1296.

10. Cugati S, Cumming RG, Smith W, Burlutsky G, Mitchell P, Wang JJ. Visual impairment, agerelated macular degeneration, cataract, and long-term mortality: the Blue Mountains Eye Study. *Archives of ophthalmology* 2007;125:917-924.

11. Foong AW, Fong CW, Wong TY, Saw SM, Heng D, Foster PJ. Visual acuity and mortality in a chinese population. The Tanjong Pagar Study. *Ophthalmology* 2008;115:802-807.

12. McCarty CA, Nanjan MB, Taylor HR. Vision impairment predicts 5 year mortality. *The British journal of ophthalmology* 2001;85:322-326.

13. Siantar RG, Cheng CY, Gemmy Cheung CM, et al. Impact of Visual Impairment and Eye diseases on Mortality: the Singapore Malay Eye Study (SiMES). *Scientific reports* 2015;5:16304.

14. Grodum K, Heijl A, Bengtsson B. Glaucoma and mortality. *Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie* 2004;242:397-401.

15. Knudtson MD, Klein BE, Klein R. Age-related eye disease, visual impairment, and survival: the Beaver Dam Eye Study. *Archives of ophthalmology* 2006;124:243-249.

16. Wang YX, Zhang JS, You QS, Xu L, Jonas JB. Ocular diseases and 10-year mortality: the Beijing Eye Study 2001/2011. *Acta ophthalmologica* 2014;92:e424-428.

17. Akbari M, Akbari S, Pasquale LR. The association of primary open-angle glaucoma with mortality: a meta-analysis of observational studies. *Archives of ophthalmology* 2009;127:204-210.

18. Wu SY, Nemesure B, Hennis A, et al. Open-angle glaucoma and mortality: The Barbados Eye Studies. *Archives of ophthalmology* 2008;126:365-370.

19. Hiller R, Podgor MJ, Sperduto RD, Wilson PW, Chew EY, D'Agostino RB. High intraocular

pressure and survival: the Framingham Studies. *American journal of ophthalmology* 1999;128:440-445.20. Flammer J, Orgul S, Costa VP, et al. The impact of ocular blood flow in glaucoma. *Progress in*

21. Yanagi M, Kawasaki R, Wang JJ, Wong TY, Crowston J, Kiuchi Y. Vascular risk factors in glaucoma: a review. *Clinical & experimental ophthalmology* 2011;39:252-258.

retinal and eye research 2002;21:359-393.

22. He M, Foster PJ, Ge J, et al. Prevalence and clinical characteristics of glaucoma in adult Chinese: a population-based study in Liwan District, Guangzhou. *Investigative ophthalmology & visual science* 2006;47:2782-2788.

23. Shaffer RN. Operating room gonioscopy in angle-closure glaucoma surgery. *AMA archives of ophthalmology* 1958;59:532-535.

24. Wang YX, Pan Z, Zhao L, You QS, Xu L, Jonas JB. Retinal nerve fiber layer thickness. The Beijing Eye Study 2011. *PloS one* 2013;8:e66763.

25. Cheung CY, Chen D, Wong TY, et al. Determinants of quantitative optic nerve measurements using spectral domain optical coherence tomography in a population-based sample of non-glaucomatous subjects. *Investigative ophthalmology & visual science* 2011;52:9629-9635.

26. Ramirez AI, de Hoz R, Salobrar-Garcia E, et al. The Role of Microglia in Retinal Neurodegeneration: Alzheimer's Disease, Parkinson, and Glaucoma. *Frontiers in aging neuroscience* 2017;9:214.

27. Shi Z, Zheng H, Hu J, et al. Retinal Nerve Fiber Layer Thinning Is Associated With Brain Atrophy: A Longitudinal Study in Nondemented Older Adults. *Frontiers in aging neuroscience* 2019;11:69.

28. Davis BM, Crawley L, Pahlitzsch M, Javaid F, Cordeiro MF. Glaucoma: the retina and beyond. *Acta neuropathologica* 2016;132:807-826.

29. Kirbas S, Turkyilmaz K, Anlar O, Tufekci A, Durmus M. Retinal nerve fiber layer thickness in patients with Alzheimer disease. *Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society* 2013;33:58-61.

30. Frishman WH, Kowalski M, Nagnur S, Warshafsky S, Sica D. Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: focus on beta-adrenergic blockade. *Heart disease* 2001;3:386-397.

 Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *Lancet* 2005;366:895-906.
 Burr JM, Mowatt G, Hernandez R, et al. The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. *Health technology assessment* 2007;11:iii-iv, ix-x, 1-190.

33. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. *Archives of ophthalmology* 2002;120:1268-1279.

Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. *Archives of ophthalmology* 2002;120:701-713; discussion 829-730.
 Muskens RP, Wolfs RC, Witteman JC, et al. Topical beta-blockers and mortality. *Ophthalmology*

1 2 3 4 5 6 7 8	 2008;115:2037-2043. 36. Glynn RJ, Knight EL, Levin R, Avorn J. Paradoxical relations of drug treatment with mortality in older persons. <i>Epidemiology</i> 2001;12:682-689. 37. Stein JD, Newman-Casey PA, Niziol LM, Gillespie BW, Lichter PR, Musch DC. Association
9 10	between the use of glaucoma medications and mortality. <i>Archives of ophthalmology</i> 2010;128:235-240.38. Lee AJ, Wang JJ, Kifley A, Mitchell P. Open-angle glaucoma and cardiovascular mortality: the
11	Blue Mountains Eye Study. <i>Ophthalmology</i> 2006;113:1069-1076.
12 13	
14 15	
16 17	
18 19	
20 21	
22 23	
24 25	
26 27	
28 29	
30 31	
32 33	
34 35	
36 37	
38 39	
40 41 42	
42 43 44	
44 45 46	
40 47 48	
49 50	
50 51 52	
52 53 54	
55 56	
57 58	
59 60	20

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

able 1 Baseline Characteristics of pa	articipants with POA	G, PACG, PA(C and PACS.	mjopen-2020-040795 on 7 Oc 1 by copyright, including for		
Basic characteristics	Normal, N		PAC	CD uses		_ POAG, N (%)
	(%)	PACS, N	PAC, N (%)	PAQ	Total, N	
Total number (%)	1153(100)	136 (100)	33 (100)	21 (5 1 1 1 1 1 1 1 1 1 1	190 (100)	29 (100)
Age (%)				vnloa Supe ext a		
50-59	440 (38.2)	17 (12.5)	5 (15.2)		22 (11.6)	4 (13.8)
60-69	328 (28.5)	46 (33.8)	12 (36.4)	5 (2300)	63 (33.2)	7 (24.1)
+70	385 (33.4)	73 (53.7)	16 (48.5)		105 (55.3)	18 (62.1)
Female (%)	639 (55.4)	95 (69.9)	26 (78.8)	13 (🔄 1.🙀)	134 (70.5)	8 (27.6)
No more than middle school	809 (79.3)	93 (79.5)	19 (63.3)	12 (a)	124 (75.6)	22 (78.6)
Income less than 1000RMB	585 (72.7)	78 (82.1)	22 (88.0)	12 (22.8)	112 (84.2)	19 (70.4)
BMI (kg/m²)				n/ on		
Normal (18.5-30.0)	716 (91.6)	79 (85.0)	16 (72.7)	y similar (%chi	106 (82.8)	23 (88.5)
Under weight (<18.5)	39 (4.99)	14 (15.1)	3 (13.6)		18 (14.1)	3 (11.5)
Over weight (≥30.0)	27 (3.45)	0 (0)	3 (13.6)	1 (1, 69)	4 (3.13)	0 (0)
Hypertension (%)	416 (40.1)	61 (45.9)	15 (45.5)	10 (50 🛱)	86 (46.2)	16 (57.1)
Diabetes (%)	105 (10.1)	16 (12.0)	3 (9.09)	4 (20.0)	23 (12.4)	3 (10.7)
		21		ibliographique		

23 of 29			BMJ Open		mjopen- d by cop			4
					mjopen-2020-040795 J by copyright, includ			
-	PVI (%)	228 (19.8)	45 (33.3)	12 (36.4)	10 (⁵ 7.6)	67 (35.5)	13 (44.8)	
	CCT(µm)	541.7±33.2	535.5±33.4	542.9±29.8	ዓ o 550. ⁄{፮‡<u>ନ</u>୍ପଟ ୍ଟ.9	538.4±32.5	542.5±35.2	
	IOP (mmHg, SD)	15.2±3.04	15.1±2.88	14.8±4.25	s s be 19.4a±ge 326	15.5±3.71	15.8±2.87	
-	Abbreviations: PACD=Primary a	angle closure disease, POA	C=Primary op	en angle glauco	oma, PAGG= F	Primary angle cl	osure	
ç	glaucoma, PAC= Primary angle					k, PVI=Presentii	ng visual	
i	mpairment, CCT=central corne	a thickness, IOP=Intraocula	ar pressure		berieu and c			
					ir (AE data r			
					rom http:/ (ABES) . ata mining			
). 19, A			
					njop I trai			
					en.br ning			
					, and			
					//bmjopen.bmj.com/ on June 13, 2025 a			
					n Ju ilar t			
					lune 13, techno			
					3, 2025 ologies			
					25 a lies.			
					t Ag			
					enc			
					e Bi			
					blio			
			22		grap			
					Agence Bibliographique			
					ue d			
		For peer review only - http://	bmjopen.bmj.com	n/site/about/guideli	nes.xhtml			

Basic Factors	Died, N (%)	Alive, N (%)	P-value
Total number (%)	306 (100)	1066 (100)	
Age (%)			<0.001
50-59	23 (7.52)	443 (41.6)	
60-69	66 (21.6)	332 (31.1)	
+70	217 (70.9)	291 (27.3)	
Female (%)	147 (48.0)	634 (59.5)	<0.001
No more than middle school	155 (67.7)	800 (81.4)	<0.001
Income less than 1000RMB	173 (83.2)	543 (71.7)	0.001
BMI (kg/m²)			0.009
Normal (18.5-30.0)	169 (85.8)	676 (91.5)	
Under weight (<18.5)	22 (11.2)	38 (5.14)	
Over weight (≥30.0)	6 (3.05)	25 (3.38)	
Hypertension (%)	111 (44.4)	407 (40.6)	0.277
Diabetes (%)	33 (13.2)	98 (9.79)	0.120
PVI (%)	120 (39.5)	188 (17.6)	<0.001
VCDR(mean±SD)	0.49±0.18	0.44±0.17	<0.001
Age (%) 50-59 60-69 +70 Female (%) No more than middle school Income less than 1000RMB BMI (kg/m ²) Normal (18.5-30.0) Under weight (<18.5) Over weight (≥30.0) Hypertension (%) Diabetes (%) PVI (%) VCDR(mean±SD) CCT(µm) IOP (mmHg, SD)(mean±SD) Abbreviations: PACD=Primary angle	540.3±35.3	541.5±32.5	0.582
IOP (mmHg, SD)(mean±SD)	15.1±3.32	15.3±3.08	0.495

Table 2 Distribution of Basic Characters Associated with Mortality at Baseline Examination.

Abbreviations: PACD=Primary angle closure disease, POAC=Primary open angle glaucoma, PACG= Primary angle closure glaucoma, PAC= Primary angle closure, PACS= Primary angle closure suspect, BMI=Body mass index, PVI=Presenting visual impairment, VCDR= vertical cup-to-disc ratio, CCT=central cornea thickness, IOP=Intraocular pressure.

29				BMJ Open	mjopen-2020-040 J by copyright, in		
-	Table 3 Cox Proportional Hazards N				including for us gle Status.		59/ CI)
		Participants, N	Died, N	Mortality Rate, %(95%Cl)	Univariabe Univariabe to	Age and Gender Adjusted	5% CI) Multivariabl Adjusted†
-	Angle Status	0) text a	j	
	Normal	1153	235	20.4 (18.1,22.8)	Reference	Reference [1]	Reference [1
	PAC	33	10	30.3 (15.6,48.7)	1.41(0.75,2 3 6,5)	1.27 (0.67,2.39)	0.85 (0.37,1.9
	PACS	136	43	∕31.6 (23.9,40.1)	1.59(1.15,2-19)	1.32 (0.95,1.83)	1.27 (0.84,1.9
	PACG	21	10	47.6 (25.7,70.2)	≥ <u></u> 2.63(1.40,4 5 95 9	2.15 (1.14,4.04)	1.60 (0.70,3.6
	PACD (PAC+PACS+PACG)	190	63	33.2 (26.5,40.3)	1.74(1.32,2,330)	1.46 (1.10,1.95)	1.25 (0.87,1.7
	POAG	29	8	27.6 (12.7,47.2)	1.31(0.65,2 2 65 8 65 8 65 8 65 8 65 8 65 8 65 8 6	0.74 (0.36,1.49)	0.70 (0.32,1.5
	Any glaucoma (PACG+POAG)	50	18	36.0 (22.9,50.8)	1.85(1.15,2=97§	1.18 (0.73,1.91)	0.96 (0.54,1.7
/	Abbreviations: PAC= Primary angl	e closure, PAC	S= Prima	ary angle closure si	uspect, PAC 🛱 🖣 r	mary angle closure	glaucoma,
I	PACD=Primary angle closure diseas	se, POAG=Prima	ary open	angle glaucoma, HR	يَ 5 Hazard ratiog Cierce:	Confidence interval.	
-	† Adjusted for age, gender, educatio	on, income, body	r mass ind	dex, presenting visua	es. 25 atoo s. atoo gence Bibliographique	ry of diabetes and hy	pertension.
		For peer review only	- http://bm	jopen.bmj.com/site/abou	0		

able 4 Cox Proporti	onal Hazards Mc	odels of 1	BMJ O 0 Year Mortality Cate		mjopen-2020-040795 on 7 O 1 by copyright, including for R.		Page 2
	Participants,	Died,	Mortality		H∰ ∰5% CI)		-
	N	Ν	Rate, %(95%CI)	Univariable	Age a the second	Multivariable	_
				Univaliable	A đ ặ şted	Adjusted†	
IOP		Or			nload Superi		_
Unit increase	-	-	50-	1.02(0.99,1.05)	1.02 20, 1.05)	1.02 (0.99,1.05)	
10~21	1267	272	21.5(19.2,23.8)	Reference [1]		Reference [1]	
<10	43	12	27.9(15.3,43.7)	1.32(0.74,2.35)	1.16 0.68,1.99)	0.91 (0.44,1.89)	
>21mmHg	50	14	28.0(16.2,42.5)	1.34(0.78,2.28)	0.97 20.48,1.97)	0.97 (0.49,1.91)	
VCDR					ning,		
Unit increase	-	-	-	3.86(2.05,7.26)	1.76 هَرْ 0.94,3.30)	1.59 (0.74,3.46)	
<u><</u> 0.3	453	68	15.0(11.8,18.6)	Reference [1]	Reference [1]	Reference [1]	
>0.3	867	209	24.1(21.3,27.1)	1.71(1.30,2.25)	1.53 § 1. 5 6,2.01)	1.60 (1.11,2.33)	

* Adjusted for age, gender, education, income, body mass index, presenting visual impairment, his pory of diabetes and hypertension. 25 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

 mjopen-2020-040795 J by copyright, includ

13, 2025 at Agence Bibliographique de l

Supplement Table	Cox Proportional Hazards Models of 10 Year Mortality Categorized by VC DR d	ifforont out off
Supplement lable	Cox Proportional Hazards models of To Teal Mortality Categorized by Voor	

	Participants,	Died,	Mortality		HRភ្ល(ឮទី% CI)	
	N	N Rate, %(95%Cl) Univariable		Age and be and b	Multivariable Adjusted†	
VCDR		0.			t Sup t ext	
<u><</u> 0.5	1012	197	19.5(17.1,22.0)	Reference [1]	Refe te ringe [1]	Reference [1]
>0.5	308	80 🧹	26.0(21.2,31.2)	1.37(1.06,1.78)	1.10 ()	1.11 (0.82,1.51)
VCDR					ES) . ining,	
<0.7	1160	229	19.7(17.5,22.2)	Reference [1]	Referente [1]	Reference [1]
<u>></u> 0.7	160	48	30.0(23.0,37.7)	1.62(1.18,2.20)	1.16 (B .84, 1.59)	1.15 (0.80,1.67)

Abbreviations: IOP=Intraocular pressure, VCDR=Vertical cup disc ration, HR= Hazard ratio, CI=

t Adjusted for age, gender, education, income, body mass index, presenting visual impairment, tisk by of diabetes and hypertension

BMJ Open STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of coeffort studies

Section/Topic	ltem #	Recommendation Cc tober	Reported on page #
Title and abstract	1	(<i>a</i>) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what $\sqrt{a^2}$ found	3-4
Introduction		(c) riolide in the distinct and balanced balanced balanced balanced balanced balanced balanced to the dist the distinct th	
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods		Al trai	
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, and data collection	7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if	7-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measure ment). Describe comparability of assessment methods if there is more than one group	7-9
Bias	9	Describe any efforts to address potential sources of bias	7-9

Page	29	of	29
------	----	----	----

BMJ Open

29		BMJ Open BMJ Open 2020- BMJ Open 2020- BMJ Open	
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which good in the analyses of the second secon	8,10
Statistical methods	12	(<i>a</i>) Describe all statistical methods, including those used to control for confounding	10
		(b) Describe any methods used to examine subgroups and interactions	10
		(c) Explain how missing data were addressed ල් සූ වි ල් ගුන්	10
		(d) If applicable, explain how loss to follow-up was addressed	
		(e) Describe any sensitivity analyses	
Results		http://	
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, example for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10-11
		(b) Give reasons for non-participation at each stage	11
		(c) Consider use of a flow diagram	
Descriptive data	14*	(c) Consider use of a flow diagram (a) Give characteristics of study participants (eg demographic, clinical, social) and information of exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest	11
		(b) Indicate number of participants with missing data for each variable of interest	11
		(c) Summarise follow-up time (eg, average and total amount)	11
Outcome data	15*	Report numbers of outcome events or summary measures over time	11
Main results	16	(<i>a</i>) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision being the stimates and their precision being the stimates and	11-12

3 4

		BMJ Open BMJ Open (b) Report category boundaries when continuous variables were categorized including for the provided of the p	
		(b) Report category boundaries when continuous variables were categorized 5	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful megeriod	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	12
Discussion		Summarise key results with reference to study objectives	
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss limitations of the study are study and the study are stu	15-16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity and the relevant evidence	12-15
Generalisability	21	Discuss the generalisability (external validity) of the study results	12-15
Other information		trainin	
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	2
*Give information sepa	arately fc	or cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in controls in case-control studies and, if applicable, for exposed and unexposed groups in controls in case-control studies and if applicable, for exposed and unexposed groups in controls in case-control studies and if applicable, for exposed and unexposed groups in controls in case-control studies and if applicable, for exposed and unexposed groups in controls in case-control studies and if applicable, for exposed and unexposed groups in controls in case-control studies and if applicable, for exposed and unexposed groups in controls in case-control studies and if applicable, for exposed and unexposed groups in controls in case-control studies and if applicable, for exposed and unexposed groups in controls in case-control studies and if applicable, for exposed and unexposed groups in controls in case-control studies and if applicable, for exposed and unexposed groups in controls in case-control studies and if applicable, for exposed and unexposed groups in controls in case-control studies and it is applied by the control studies	nal studies.
checklist is best used in	n conjuno	bration article discusses each checklist item and gives methodological background and published examples of transparent reportion with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine bidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.spobe-statement.org.	
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open

BMJ Open

Association of Glaucoma with Ten-Year Mortality in a Population-based Longitudinal Study in Urban Southern China: The Liwan Eye Study

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-040795.R1
Article Type:	Original research
Date Submitted by the Author:	30-Aug-2020
Complete List of Authors:	Wang, Langhua; Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology Zhu, Zhuoting; Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology Huang, Wenyong; Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology Scheetz, Jane; Centre for Eye Research Australia Ltd He, Mingguang; Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology
Primary Subject Heading :	Ophthalmology
Secondary Subject Heading:	Epidemiology, Public health
Keywords:	Glaucoma < OPHTHALMOLOGY, EPIDEMIOLOGY, PUBLIC HEALTH, OPHTHALMOLOGY

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

1	Association of Glaucoma with Ten-Year Mortality in a Population-based
2	Longitudinal Study in Urban Southern China: The Liwan Eye Study
3	
4	Running tilt: Glaucoma and mortality
5	Research question: The association between glaucoma and ten-year
6	mortality in an adult population in China
7	Study design: Population-based cohort study
8	
9	Authors
10	Lanhua Wang MD, PhD ^{1*}
11	Zhuoting Zhu MD, PhD ^{1*}
12	Wenyong Huang MD, PhD ¹
13	Jane Scheetz, PhD ²
14	Mingguang He MD, PhD ¹
15	
16	*These authors contributed equally to this study.
17	
18	Institutions
19	1. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center,
20	Sun Yat-sen University, Guangzhou, China
21	2. Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital,
22	Melbourne, Australia
23	1

2							
3 4	1	Financial support: Supported by the Fundamental Research Funds of the					
5 6	2	State Key Laboratory of Ophthalmology, National Natural Science Foundation					
7	3	of China (81420108008 and 81570843H1204), and Science and Technology					
8 9	5	\circ					
) 10 11	4	Planning Project of Guangdong Province, China 2013B20400003.					
12 13	5	Conflict of Interest: The authors have no financial or other conflicts of					
14 15	6	interest concerning this study.					
16 17	7	Data availability: Data are available upon reasonable request.					
18 19 20	8	Correspondence:					
21 22	9	Prof Mingguang He					
23 24 25	10	State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun					
26 27	11	Yat-sen University					
28 29 30	12	Guangzhou 510060, People's Republic of China					
31 32 33	13	Email: mingguanghe@gmail.com					
34 35	14						
36 37 38	15						
39 40	16	Word count: Abstract:296; Whole paper: 3058.					
41 42 43	17	Tables: 4 Figure: 1					
44 45 46	18						
47 48	19						
49 50 51	20						
52 53	21						
54 55 56	22						
57 58	23						
59 60		2					

1 Abstract

Objectives: To investigate the association between glaucoma and ten-year
 mortality rate in an adult population in China.

Design: Population-based cohort study.

Setting: The Liwan Eye Study.

Participants: 1405 baseline participants aged 50 years and older were invited
to attend a ten-year follow-up examination.

Primary and secondary outcome measures: The International Society of Geographic and Epidemiologic Ophthalmology criteria was used to define glaucoma. Detailed information of mortality was confirmed using the Chinese Centre for Disease Control and Prevention. Presenting visual impairment (PVI) was defined as a presenting visual acuity of less than 20/40 in the better-seeing eye. The ten-year mortality rates were compared using the log-rank test. Cox proportional hazards regression models were used to investigate the association between glaucoma and mortality. **Results:** A total of 1372(97.7%) participants with available gonioscopic data were included in the analysis. Of these, 136(9.9%), 33(2.4%) and 21(1.5%) participants had primary angle closure suspect (PACS), primary angle closure (PAC) and primary angle closure glaucoma (PACG), and 29(2.1%) had primary open angle glaucoma (POAG). After ten years, 306 (22.3%) participants were deceased. The ten-year mortality was significantly associated with PACG(HR,2.15,95%CI:1.14-4.04) but not associated with PAC, PACS and POAG when age and gender were adjusted for. This association was no longer statistically significant when co-variables, such as income, education, body mass index, PVI, history of diabetes and

26 hypertension, were adjusted for. Larger vertical cup-to-disc ratio (VCDR>0.30)

27 was only a significant risk factor in multivariable analysis

1 2		
2 3 4 5	1	(HR,1.60;95%Cl,1.11-2.33).
6	2	Conclusions: PACG was significantly associated with higher long-term
7 8	3	mortality but this association was likely to be confounded by other systemic
9 10	4	risk factors. VCDR>0.3 was the only independent predictor, implying that it
11 12	5	may be a marker of ageing and frailty.
13 14	ć	Defined and Dublic loss homent Ofstans at Manufactor and public some
15 16	6	Patient and Public Involvement Statement: No patients and public were
17 18	7	involved in the design and process of this study.
19 20	8	Key words: Glaucoma; Mortality; China; Cox proportional hazards regression
21 22	9	model
23	10	model
24 25	10	
26 27	11	
28 29	12	
30 31		
32 33	13	
34 35	14	
36 37	15	
38	15	
39 40	16	
41 42	17	
43 44		
45 46	18	
47 48	19	
49	• •	
50 51	20	
52 53	21	
54 55	22	
56 57	22	
58 59	23	
60		4

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1		
2 3		
4	1	Strengths and limitations of this study
5		
6 7	2	1. The present study was a population-based cohort study which utilized a
8 9	3	standardized study protocol
10 11	4	2. The International Society of Geographic and Epidemiologic Ophthalmology
12 13	5	criteria was used to define glaucoma
14	5	
15 16	6	3. Study limitations include the following: 1) small number of patients with
17 18	7	glaucoma;2) several important confounding factors, such as smoking status
19 20	8	were not available.
21 22	9	
23		
24 25	10	
26		
27 28	11	
28 29		
30	12	
31 32		
33	13	
34		
35 36	14	
37		
38	15	
39 40	16	
41	16	
42 42	17	
43 44	17	
45	18	
46 47	10	
47 48	19	
49	17	
50 51	20	
52		
53	21	
54 55		
56	22	
57		
58 59	23	
60		5

1 Introduction

Glaucoma is one of the leading causes of irreversible visual impairment (VI) and blindness worldwide, affecting approximately 64.3 million people .¹ It has been estimated that the number of people diagnosed with glaucoma in China was 13.1 million in 2015, more than half of which were diagnosed with primary angle closure glaucoma(PACG).² With the current ageing population, this number is expected to reach 15.2 million by 2050.²

In addition to its impact on vision and quality of life, some studies have reported that patients with glaucoma have higher rates of mortality,³⁻⁶ while others found no association,⁷⁻¹⁸ Disparate findings have led to controversies regarding the risk of premature mortality of patients with glaucoma. Similarly, inconsistent evidence has been observed regarding the association between levels of intraocular pressure (IOP), a well-established functional risk factor for glaucoma, and survival.^{14, 17, 18} The relationship between mortality and vertical cup-to-disc ratio (VCDR), a robust structural indicator of glaucomatous loss of the neuroretinal rim, has been exclusively investigated in the Andhra Pradesh Eye Disease Study (APEDS), implying that nerve fiber loss may be a marker of ageing and frailty.⁷ Of note, previous studies, mainly in white and black populations, investigated the relationship between primary open angle glaucoma (POAG), elevated IOP and long-term survival.^{8-10, 12, 14, 15, 18, 19} In comparison, few studies have been conducted in Asian populations.^{3, 4, 7, 11, 13,} ¹⁶ Furthermore, dominant subtypes, clinical presentations and the underlying pathogenesis of glaucoma in Asian populations vary from those in white and black populations.^{20, 21} A better understanding of the relationship between different subtypes of glaucoma (POAG and primary angle closure disease (PACD)), level of IOP, VCDR and risk of mortality may provide insights into the potential mechanisms and clinical management of glaucoma.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

1 Therefore, the aim of this study was to explore the relationship between

2 different types of glaucoma, level of IOP, VCDR and ten-year mortality in an

3 adult population in southern urban China.

Methods

6 Study Population

A detailed description of the methodology utilized in the Liwan Eye Study has been described previously.²² Briefly, the Liwan Eye Study was a population-based cohort study that commenced in 2003 with a five-year follow-up (2008 to 2009) and a ten-year follow-up (2013), both follow-up examinations followed an identical protocol. At baseline, 75.4% (1405 of 1864) of eligible participants underwent a comprehensive eye examination and a questionnaire regarding income, education, and medical history. All participants in the baseline study were invited back for the five- and ten-year follow-up examinations. A total of 924 participants (75.0% of survivors, 79.1% of eligible participants) returned for the five-year examination and 791 (73.8% of survivors, 86.2% of eligible participants) for the ten-year examination.

Ethical approval for the study was obtained from the Zhongshan University Ethics Review Board, and the Research Governance Committee of Moorfields Eye Hospital, London. The study was conducted in accordance with the tenets of the World Medical Association's Declaration of Helsinki. Written informed consent was obtained from all participants.

25 Study procedure

26 All participants had their presenting visual acuity (PVA) tested using an Early

Page 9 of 30

BMJ Open

Treatment Diabetic Retinopathy Study (ETDRS) vision chart whilst wearing their habitual refractive correction. Best-corrected visual acuity (BCVA) was measured for those with PVA \leq 20/40 in either eye. Presenting visual impairment (PVI) was defined as PVA less than 20/40 in the better-seeing eye. The IOP was measured before mydriasis by a handheld tonometer (Tonopen; Mentor, Norwell, Massachusetts, USA) with three consecutive measurements of an achieved standard error of <5%. Central cornea thickness (CCT) was evaluated using an ultrasound pachymetry (Echoscan US1800; Nidek, Corp). Height and weight were measured without shoes, using a standard calibrated scale. Body mass index (BMI) was calculated as the weight in kilograms divided by the square of the height in centimeters and was divided into three groups: underweight (BMI <18.5 kg/m²), normal to overweight (18.5 to 30 kg/m²), or obese (BMI \geq 30.0 kg/m²). Diabetes mellitus (DM) and hypertension were based on self-reported history of a diagnosis and/or previous medication use.

Slit-lamp examination (TopconSL-8Z, Tokyo, Japan) with a 78-diopter lens was used to identify abnormalities of the anterior segment and posterior segment by an experienced ophthalmologist (MH). Detailed information of the gonioscopic examination in the Liwan Eye Study has been described previously.²² Briefly, all participants underwent slit lamp based static and dynamic gonioscopy with a Goldmann-type, one-mirror lens (Haag Streit, Bern, Switzerland) at 25x magnification by the same experienced specialist-trained ophthalmologist (MH). Narrow angle and open angle were stratified by status of the iris insertion and recorded using five categories by the Shaffer system. ²³According to the International Society of Geographical and Epidemiological Ophthalmology (ISGEO) classification, primary angle closure suspect (PACS) was defined as simply an angle in which ≥270° of the

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

> pigmented trabecular meshwork cannot be seen without evidence of trabecular obstruction and glaucomatous damage. Primary angle closure (PAC) was defined as eyes with PACS and features of peripheral anterior synechiae, elevated IOP, iris wholing, or excessive pigment deposition on the trabecular surface, but no evidence of glaucomatous damage. Primary angle closure glaucoma (PACG) was defined as eyes with PAC and evidence of glaucomatous damage. Participants with PACS, PAC or PACG were grouped as PACD.

The optic disc was assessed using a 78-D lens at 16x magnification. The VCDR was used as key indicator of structural glaucomatous change. Visual field (VF) assessment was performed in those with a VCDR of >0.7(97.5th percentile of the Liwan Eye Study) in either eye, VCDR asymmetry >0.2 or IOP of >21 mm Hg on a subsequent day. The definition of glaucoma was based on three levels of evidence using ISGEO criteria. The division of POAG and PACG was based on the gonioscopic results of narrow angle or open angle. If glaucoma status or VCDR were observed in both eyes, the eye with more severe status or larger VCDR value was used in the analysis.

Detailed data from the Chinese Centre for Disease Control and Prevention (CDC) were used to confirm the mortality of participants during the ten-year follow-up period. After providing the CDC with a list of names, age, year of birth, gender and latest address for the participants suspected of having passed away, based on which researchers at the CDC provided a corresponding list of "matched" deaths with dates and causes. The causes of death recorded by the CDC were documented on the death certificates using the International Classification of Diseases, Ninth Revision.

Page 11 of 30

BMJ Open

1 Statistical analysis

All statistical analyses were performed using Stata (ver. 10.0; Stata Corp. College Station, TX). The student's t-test was used to compare continuous variables, while Pearson chi squire or Fisher's exact test for the comparison of categorical data. Survival times were calculated for each participant from the date of baseline examinations to the date of death or April 30, 2014. Univariable and multivariable Cox proportional hazard regression models were used to test the associations between mortality and baseline PACS, PAC, PACG, POAG, IOP and VCDR after adjusting for baseline characteristics of age, gender, education level, family income, history of diabetes and hypertension and PVI. Analysis of IOP and VCDR were based on both continuous and categorical level. IOP was divided into three categorical groups: 10-21mmHg (reference group), <10mmHg and >21 mmHg. The lowest quartile of VCDR (≤ 0.3), the third quartile of VCDR in this population (<0.5) and VCDR of < 0.7 (97.5th percentile of the Liwan Eye Study) were used as the reference group to assess associations of different VCDR cut-offs with long-term survival. Hazard ratios (HR) and 95% confidence intervals (CI) were given. A proportional hazard test was used to check the assumption of cox proportional hazards model, and the log-rank test was used to compare different groups with respect to their survival distributions.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Results

Of the 1405 participants at baseline, 33 were excluded (30 without
gonioscopic data, 3 with secondary glaucoma and 1 with un-classified reason
du to cataract surgery), leaving 1372 participants with complete data available
for analysis. Among the 1372 participants, the prevalence of PACS, PAC,

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

PACG, and POAG was 9.9% (136 participants), 2.4% (33 participants), 1.5% (21 participants), and 2.1% (29 participants), respectively (Figure 1). Compared to the 1153 normal participants, those with PACD were more likely to be older (P<0.001), female (P=0.001), underweight (P<0.001), of a lower level of family income (P=0.005) and have a higher proportion of PVI (P<0.001). There were no statistically significant differences between groups in terms of level of education, hypertension, diabetes, CCT and IOP. Compared to the 1,153 normal participants, those with POAG tended to be older (P=0.003), male (P=0.003) and had a higher proportion of PVI (P=0.001) (Table 1). By the end of April 2014 (median follow-up length: 9.38 years; range: 0.15-10.4), 306 (22.3%) of the 1,372 participants passed away, 294 (21.4%) did not return for re-examination because they declined participation (126), relocated (122) or were uncontactable (41), leaving 777(56.6%) at the ten-year follow-up examination. Detailed follow-up information can be found in Figure 1. Those who passed away tended to be older (P<0.001), male (P<0.001), have a lower level of educational attainment (P=0.001), lower family income (P<0.001), higher proportion of PVI (P<0.001), larger VCDR (P<0.001) and be underweight (P=0.009). The medical history of hypertension and diabetes, CCT and mean IOP value were similar between the two groups (Table 2). Among the 1153 participants without PACD or POAG, 235 (20.4%, 95%CI=18.1, 22.8%) passed away during the ten-year follow up period. The ten-year mortality rate of the 1153 participants was significantly lower than those with PACS (43/136, 31.6%, 95%CI= 23.9, 40.1%), PAC (10/33, 30.3%, 95%CI= 15.6, 48.7%), PACG (10/21, 47.6%, 95%CI=25.7, 70.2%), and POAG

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1	(8/29, 27.6%, 95%CI= 12.7, 47.2%). The age and gender adjusted cox
2	proportional hazards model showed that the presence of PACG (HR=2.15,
3	95% CI=1.14, 4.04), PACD (HR=1.46, 95% CI=1.10, 1.95) and a VCDR of
4	more than 0.3 (HR=1.53, 95% CI=1.16, 2.01) were significantly associated
5	with a higher risk of mortality. No association was found between mortality
6	and PACS, PAC, POAG and level of IOP. After adjusting for age, gender,
7	education, income, history of diabetes and hypertension, BMI and PVI, the
8	significant association between VCDR of more than 0.3 and poorer survival
9	rate was still observed (HR=1.60, 95% CI=1.11, 2.33) (Table 3 and Table 4).
10	A strong associations between ten year mortality and a VCDR>0.5
11	(HR=1.37, 95% CI=1.06, 1.78) and VCDR≥0.7 (HR=1.62, 95% CI=1.18, 2.20)
12	were found in the univariable analysis, whereas these associations
13	disappeared after adjusting for confounders (all P>0.05, Supplement Table 1).
14	
15	Discussion
16	In this population-based cohort study, we found a higher crude mortality rate
17	among patients with POAG and any form of PACD (ranging from 7.2% to
18	27.2%). However, this difference was not replicated after multivariable
19	confounders were adjusted for. Level of IOP was not significantly associated
20	with an increased risk of ten-year mortality in the multivariable model, while
21	VCDR of more than 0.3 was an independent predictor of long-term poor
22	survival.
••	

Controversy still exists around the association between POAG and the
increased risk of mortality.^{3-10, 12, 14-16, 18, 19} Almost 50 years ago, Egge et al
found a decreased 30-year survival rate for patients with glaucoma in Norway.
This finding was more pronounced among men using acetazolamide.⁶ Results

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

of the National Health Interview Survey (NHIS) 1986-1994 also supported the finding that glaucoma was related to an increased risk of all-cause and cardiovascular disease mortality among adults residing in the United States.⁵ However, the glaucoma-mortality association in the NHIS is likely to have been impacted by recall bias (self-reported definition of glaucoma), misclassification error and underestimation of glaucoma cases. Furthermore, the diagnostic methods, definition and treatments of glaucoma have changed over the past five decades, making its findings less generalizable to today's glaucoma patients. More recent studies are in favor of the finding that POAG is not significantly associated with long-term survival.^{3, 4,7-10, 12, 14-16, 18} The non-significant relationship in these studies are in agreement with the findings of our study. Differences in ethnicity, age distribution, study design, length of follow-up, definition of glaucoma, and confounding variables adjusted for in the multivariate model may explain the inconsistent results between studies. Alternatively, the small number of patients with POAG in the current study (n=29) may also explain the lack of association between POAG and ten-year mortality. However, a recent meta-analysis of observational studies¹⁷ supported the finding of a non-significant relationship between POAG and risk of mortality.

Few studies have explored the relationship between different types of PACD and mortality. Similar to the current study, previously investigations have reported that the presence of PACD was not an independent risk factor for all-cause mortality.^{7, 11, 13, 16} Thus far, only five-year data from the Beijing Eye Study has reported that the presence of PACG was related to an increased risk of mortality using multivariate analysis.^{3, 4} Interestingly, the ten-year data from the Beijing Eye Study found that mortality was not significantly associated with PACG.¹⁶ Neither the Tanjong Pagar Study¹¹ or the Singapore

BMJ Open

Malay Eye Study (SiMES)¹³ found significantly reduced survival among those with glaucoma. In the current study, we found that PACG was significantly associated with ten-year mortality in the age and gender adjusted model, but this significant association was not found in the multivariate model. This is likely due to other confounding factors not accounted for and the relatively small sample size.

The results of this study found a non-significant association between the level of IOP and ten-year mortality rate. Previous reports on the relationship between all-cause mortality and elevated IOP have been inconsistent.^{7, 14, 18, 19} Excess all-cause mortality associated with ocular hypertension was found in the Barbados Eye Study and the Framingham Study,¹⁸ while the APEDS⁷ and a Swedish study¹⁴ found no statistically significant association between elevated IOP and mortality risk. The APEDS was the only study to explore the association between VCDR and all-cause mortality. Consistent with the APEDS's finding that increasing VCDR was a predictor of ten-year mortality,⁷ we also reported a significantly increased risk of mortality among participants with VCDR of more than 0.3. Considering that previous studies have indicated that global retinal nerve fiber layer decreased significantly with age and larger VCDR,^{24, 25} one can speculate that the potential mechanism underlying the VCDR-mortality association may be caused by retinal nerve fiber layer thinning, a marker of ageing and frailty. Furthermore, the close relationship between neurodegenerative diseases (e.g., Alzheimer's disease and Parkinson's disease) and glaucoma, and the strong link between retinal nerve fiber layer thinning and brain pathology adds weight to our speculation.²⁶⁻²⁹ The non-significant association of other cut-offs, or linear of VCDR with all-cause mortality after adjusting for confounders might be due to the small sample size or non-linear relationship in our study. Alternatively, we can only

Page 16 of 30

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

speculate that VCDR of less than 0.3 (i.e., sufficient retinal nerve fibre layer)
which represent physiological process of aging or neurodegeneration might be
the threshold for better survival. Further studies with a larger study sample are
needed to investigate the association between VCDR, retinal nerve fiber layer
thickness and mortality.

Even though the mechanisms underlying the association between glaucoma/ocular hypertension-mortality is still unclear, it has been speculated that increased risk of mortality among patients with glaucoma or ocular hypertension might be caused by IOP-lowering treatment. Glaucoma-mortality association has been found to be more pronounced among men using acetazolamide.⁶ The excess mortality linked to timolol maleate treatment for POAG found in the Barbados Eve Study¹⁸ was also parallel to the hypothesis of this study. In the BMES, a dose-dependent pattern was observed in the association between duration of timolol maleate use and increased risk of cardiovascular disease mortality. In addition, previous studies verified the adverse effects of IOP-lowering treatments, including congestive heart failure, raised blood pressure and adverse respiratory effects.^{30, 31} However, the dose-dependent pattern observed in the BMES may be due to detection bias. Approximately 50-90% of glaucoma patients remain undiagnosed.^{7, 32} Participants in poorer health are more likely to access health care services and therefore have their glaucoma diagnosed and treated. The suggestion that detection bias is a cause of variable findings was further verified by the similar mortality rates between treated and untreated glaucoma patients in multicenter randomized glaucoma treatment trials (Early Manifest Glaucoma Trial and Ocular Hypertension Treatment Study) and the observational Rotterdam study.³³⁻³⁵ Even these two studies concluded that the use of glaucoma medications was associated with a reduced risk of mortality.^{36, 37}

Page 17 of 30

BMJ Open

Future investigations are required to assess this association further.

The strengths of the present study included the population-based study design, high participation rate, long-term follow-up, and standardized definition of glaucoma used. Of note, the present study was limited by the following points. Firstly, the small number of patients with glaucoma may explain the non-significant association between different types of glaucoma and mortality. Second, several important confounding factors, such as smoking status were not available in the present study. Nevertheless, the additional adjustment for these important confounding factors may further attenuate the magnitude of statistical significance and again verify the robustness of our results. Third, lack of data on the causes of death prevented the possibility of exploring the association between glaucoma and specific-cause mortality. Previous studies have reported a significant association between glaucoma and cardiovascular disease mortality.^{5, 38} Fourthly, the fact that only participants with suspect glaucoma (VCDR of \geq 0.7 in either eye (97.5th percentile of the Liwan Eye Study population), VCDR asymmetry >0.2 or IOP of >21 mm Hg) underwent VF assessment may underestimate the prevalence of glaucoma because participants with early glaucomatous changes may be missed. However, previous ocular history and IOP measurements were collected for each participant, possibly lowering the risk of underestimation. Fifthly, the relationship between changes in glaucoma related parameters and long-term survival were unavailable due to insufficient data and limited follow-up times. Finally, we did not collect information on utilization of IOP-lowering treatment. Further studies are required to investigate the relationship between IOP-lowering treatment and long-term survival.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

3	
4	1
5 6	2
7 8	3
9 10	4
11 12	5
13 14	6
15 16	7
17 18	8
19 20	9
21 22	10
23 24 25	11
26 27	12
28 29 30	13
31 32	14
33 34 35	15
36 37	16
38	17
39 40 41	18
42 43 44	19
45 46 47 48	20
49 50 51	21
52 53 54	22
55 56 57	23
58 59 60	

1 2

In conclusion, our findings suggest there is a higher level of crude mortality among patients with POAG, PACS or PAC. However, this difference was unable to be replicated after multivariable confounders were adjusted for. PACG was significantly associated with ten-year mortality in the age and gender adjusted model, but this significant association disappeared in the multivariable model. Level of IOP was not significantly associated with increased risk of ten-year mortality, while VCDR of more than 0.3 was an independent predictor of long-term survival. Further studies are needed to confirm these findings and to explore the association between different subtypes and treatments of glaucoma with long-term survival.

3 Acknowledgement:

Author Contributions: Study conception and design (LW, ZZ, MH); analysis and interpretation (LW, ZZ); writing of the article (LW, ZZ); critical revision of the article (WH, JS, MH); data collection (LW, ZZ, WH); administrative,

18 technical or logistic support (JS, MH).

2		
3	1	Reference
4 5	1	Relefence
6	2	1. Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. The British journal of
7	3	ophthalmology 2012;96:614-618.
8	4	2. Song P, Wang J, Bucan K, Theodoratou E, Rudan I, Chan KY. National and subnational
9 10	5	prevalence and burden of glaucoma in China: A systematic analysis. <i>Journal of global health</i>
11	6	2017;7:020705.
12	7	3. Xu L, Wang YX, Jonas JB. Glaucoma and mortality in the Beijing Eye Study. <i>Eye</i> 2008;22:434-
13	8	438.
14 15	9	4. Xu L, Wang YX, Wang J, Jonas JJ. Mortality and ocular diseases: the Beijing Eye Study.
16	10	Ophthalmology 2009;116:732-738.
17	11	 Lee DJ, Gomez-Marin O, Lam BL, Zheng DD. Glaucoma and survival: the National Health
18 19	12	Interview Survey 1986-1994. Ophthalmology 2003;110:1476-1483.
20	12	 Egge K, Zahl PH. Survival of glaucoma patients. <i>Acta ophthalmologica Scandinavica</i>
21	13	1999;77:397-401.
22	14	 Khanna RC, Murthy GVS, Giridhar P, et al. Glaucoma-associated long-term mortality in a rural
23 24	15	cohort from India: the Andhra Pradesh Eye Disease Study. <i>The British journal of ophthalmology</i>
25	10	2018;102:1477-1482.
26	17	
27 28		8. Sundqvist J, Ekstrom C. Open-angle glaucoma and mortality: A long-term follow-up study. <i>Acta</i>
28 29	19 20	ophthalmologica 2018;96:e1038-e1039.
30	20	9. Borger PH, van Leeuwen R, Hulsman CA, et al. Is there a direct association between age-related
31	21	eye diseases and mortality? The Rotterdam Study. <i>Ophthalmology</i> 2003;110:1292-1296.
32 33	22	10. Cugati S, Cumming RG, Smith W, Burlutsky G, Mitchell P, Wang JJ. Visual impairment, age-
34	23	related macular degeneration, cataract, and long-term mortality: the Blue Mountains Eye Study.
35	24	Archives of ophthalmology 2007;125:917-924.
36 27	25	11. Foong AW, Fong CW, Wong TY, Saw SM, Heng D, Foster PJ. Visual acuity and mortality in a
37 38	26	chinese population. The Tanjong Pagar Study. <i>Ophthalmology</i> 2008;115:802-807.
39	27	12. McCarty CA, Nanjan MB, Taylor HR. Vision impairment predicts 5 year mortality. <i>The British</i>
40	28	journal of ophthalmology 2001;85:322-326.
41 42	29	13. Siantar RG, Cheng CY, Gemmy Cheung CM, et al. Impact of Visual Impairment and Eye
43	30	diseases on Mortality: the Singapore Malay Eye Study (SiMES). Scientific reports 2015;5:16304.
44	31	14. Grodum K, Heijl A, Bengtsson B. Glaucoma and mortality. <i>Graefe's archive for clinical and</i>
45 46	32	experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle
46 47	33	<i>Ophthalmologie</i> 2004;242:397-401.
48	34	15. Knudtson MD, Klein BE, Klein R. Age-related eye disease, visual impairment, and survival: the
49	35	Beaver Dam Eye Study. Archives of ophthalmology 2006;124:243-249.
50 51	36	16. Wang YX, Zhang JS, You QS, Xu L, Jonas JB. Ocular diseases and 10-year mortality: the Beijing
52	37	Eye Study 2001/2011. Acta ophthalmologica 2014;92:e424-428.
53	38	17. Akbari M, Akbari S, Pasquale LR. The association of primary open-angle glaucoma with
54 55	39	mortality: a meta-analysis of observational studies. Archives of ophthalmology 2009;127:204-210.
55 56	40	18. Wu SY, Nemesure B, Hennis A, et al. Open-angle glaucoma and mortality: The Barbados Eye
57	41	Studies. Archives of ophthalmology 2008;126:365-370.
58	42	19. Hiller R, Podgor MJ, Sperduto RD, Wilson PW, Chew EY, D'Agostino RB. High intraocular
59 60		18
00		

2		
3	1	pressure and survival: the Framingham Studies. American journal of ophthalmology 1999;128:440-445.
4	2	20. Flammer J, Orgul S, Costa VP, et al. The impact of ocular blood flow in glaucoma. <i>Progress in</i>
5 6	3	retinal and eye research 2002;21:359-393.
7	4	21. Yanagi M, Kawasaki R, Wang JJ, Wong TY, Crowston J, Kiuchi Y. Vascular risk factors in
8	5	glaucoma: a review. Clinical & experimental ophthalmology 2011;39:252-258.
9 10	6	22. He M, Foster PJ, Ge J, et al. Prevalence and clinical characteristics of glaucoma in adult Chinese:
11	7	a population-based study in Liwan District, Guangzhou. <i>Investigative ophthalmology & visual science</i>
12	8	2006;47:2782-2788.
13	9	23. Shaffer RN. Operating room gonioscopy in angle-closure glaucoma surgery. <i>AMA archives of</i>
14 15	10	ophthalmology 1958;59:532-535.
16	11	
17		24. Wang YX, Pan Z, Zhao L, You QS, Xu L, Jonas JB. Retinal nerve fiber layer thickness. The
18	12	Beijing Eye Study 2011. <i>PloS one</i> 2013;8:e66763.
19 20	13	25. Cheung CY, Chen D, Wong TY, et al. Determinants of quantitative optic nerve measurements
20 21	14	using spectral domain optical coherence tomography in a population-based sample of non-
22	15	glaucomatous subjects. Investigative ophthalmology & visual science 2011;52:9629-9635.
23	16	26. Ramirez AI, de Hoz R, Salobrar-Garcia E, et al. The Role of Microglia in Retinal
24	17	Neurodegeneration: Alzheimer's Disease, Parkinson, and Glaucoma. Frontiers in aging neuroscience
25	18	2017;9:214.
26 27	19	27. Shi Z, Zheng H, Hu J, et al. Retinal Nerve Fiber Layer Thinning Is Associated With Brain
28	20	Atrophy: A Longitudinal Study in Nondemented Older Adults. Frontiers in aging neuroscience
29	21	2019;11:69.
30	22	 Davis BM, Crawley L, Pahlitzsch M, Javaid F, Cordeiro MF. Glaucoma: the retina and beyond.
31		
32 33	23	Acta neuropathologica 2016;132:807-826.
34	24	29. Kirbas S, Turkyilmaz K, Anlar O, Tufekci A, Durmus M. Retinal nerve fiber layer thickness in
35	25	patients with Alzheimer disease. Journal of neuro-ophthalmology : the official journal of the North
36	26	American Neuro-Ophthalmology Society 2013;33:58-61.
37	27	30. Frishman WH, Kowalski M, Nagnur S, Warshafsky S, Sica D. Cardiovascular considerations in
38 39	28	using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: focus
40	29	on beta-adrenergic blockade. <i>Heart disease</i> 2001;3:386-397.
41	30	31. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an
42	31	antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding
43	32	bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure
44 45	33	Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. <i>Lancet</i> 2005;366:895-906.
46	34	 Burr JM, Mowatt G, Hernandez R, et al. The clinical effectiveness and cost-effectiveness of
47	35	
48		screening for open angle glaucoma: a systematic review and economic evaluation. <i>Health technology</i>
49	36	assessment 2007;11:iii-iv, ix-x, 1-190.
50 51	37	33. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma
52	38	progression: results from the Early Manifest Glaucoma Trial. Archives of ophthalmology
53	39	2002;120:1268-1279.
54	40	34. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a
55 56	41	randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of
56 57	42	primary open-angle glaucoma. Archives of ophthalmology 2002;120:701-713; discussion 829-730.
58	43	35. Muskens RP, Wolfs RC, Witteman JC, et al. Topical beta-blockers and mortality. <i>Ophthalmology</i>
59		
60		19

1 2		
3	1	2008;115:2037-2043.
4	2	36. Glynn RJ, Knight EL, Levin R, Avorn J. Paradoxical relations of drug treatment with mortality in
5 6	3	older persons. <i>Epidemiology</i> 2001;12:682-689.
7	4	37. Stein JD, Newman-Casey PA, Niziol LM, Gillespie BW, Lichter PR, Musch DC. Association
8 9	5	between the use of glaucoma medications and mortality. Archives of ophthalmology 2010;128:235-240.
9 10	6	38. Lee AJ, Wang JJ, Kifley A, Mitchell P. Open-angle glaucoma and cardiovascular mortality: the
11	7	Blue Mountains Eye Study. Ophthalmology 2006;113:1069-1076.
12 13	8	
14	0	
15 16	9	
16 17	10	
18		
19 20	11	
20	12	
22		
23 24	13	
25	14	
26 27	15	
27 28	15	
29	16	
30 31	17	
32		
33	18	
34 35	19	
36	20	
37 38	20	
39	21	
40	22	
41 42		
43	23	
44 45	24	
46	25	
47	25	
48 49	26	
50	27	
51 52		
52 53	28	
54	29	
55 56		
57	30	
58 50	31	
59 60		20

Figure1 Flow chart showing the enrollment and follow-ups of participants in

to been teren only

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

2	
3	
4	
5	
6 7	
7 8	
o 9	
9 10	
11 12	
12	
17	
14	
12 13 14 15 16 17 18	
10	
12	
19	
20	
20	
21 22	
23	
23 24	
24 25	
26	
20	
27	
28 29	
29	
30 31 32 33 34 35	
22	
22	
27	
34	
35 36	
30 37	
37 38	
30 39	
40 41	
41	
42 43	
44	
45	
46	
40 47	
48	
49	
49 50	
50 51	
52	
52 53	
55 54	
55	
56	
57	
57 58	
50	

1

1

2

3

4

5

6

Figure legend:

the Liwan Eye Study

21

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

articipants with POA	BMJ Open G, PACG, PAC	C and PACS.	mjopen-2020-040795 on 7 C 4 by copyright, including fo		
Normal, N		PAC			_ POAG, N (%
(%)	PACS, N	PAC, N (%)	PAG	Total, N	
1153(100)	136 (100)	33 (100)	21 (1 9 9	190 (100)	29 (100)
			wnloa Supe text a		
440 (38.2)	17 (12.5)	5 (15.2)		22 (11.6)	4 (13.8)
328 (28.5)	46 (33.8)	12 (36.4)	5 (23 RB)	63 (33.2)	7 (24.1)
385 (33.4)	73 (53.7)	16 (48.5)	16 (a) 6.2)	105 (55.3)	18 (62.1)
639 (55.4)	95 (69.9)	26 (78.8)	13 (🚑 1.🙀)	134 (70.5)	8 (27.6)
809 (79.3)	93 (79.5)	19 (63.3)	12 (3 0. 6)	124 (75.6)	22 (78.6)
585 (72.7)	78 (82.1)	22 (88.0)	12 (<u>8</u> 2.8)	112 (84.2)	19 (70.4)
			m/ on simil:		
716 (91.6)	79 (85.0)	16 (72.7)	<u>م</u> 11 (هُ	106 (82.8)	23 (88.5)
39 (4.99)	14 (15.1)	3 (13.6)		18 (14.1)	3 (11.5)
27 (3.45)	0 (0)	3 (13.6)	1 (1 , 69)	4 (3.13)	0 (0)
416 (40.1)	61 (45.9)	15 (45.5)	10 (50 🏹)	86 (46.2)	16 (57.1)
105 (10.1)	16 (12.0)	3 (9.09)	4 (20.0)	23 (12.4)	3 (10.7)
	Normal, N (%) 1153(100) 440 (38.2) 328 (28.5) 385 (33.4) 639 (55.4) 809 (79.3) 585 (72.7) 716 (91.6) 39 (4.99) 27 (3.45)	articipants with POAG, PACG, PACNormal, N(%)PACS, N1153(100)136 (100) 440 (38.2)17 (12.5)328 (28.5)46 (33.8)385 (33.4)73 (53.7)639 (55.4)95 (69.9)809 (79.3)93 (79.5)585 (72.7)78 (82.1)716 (91.6)79 (85.0)39 (4.99)14 (15.1)27 (3.45)0 (0)	articipants with POAG, PACG, PAC and PACS.Normal, NPAC, N(%)PACS, NPAC, N (%)1153(100)136 (100)33 (100)440 (38.2)17 (12.5)5 (15.2)328 (28.5)46 (33.8)12 (36.4)385 (33.4)73 (53.7)16 (48.5)639 (55.4)95 (69.9)26 (78.8)809 (79.3)93 (79.5)19 (63.3)585 (72.7)78 (82.1)22 (88.0)716 (91.6)79 (85.0)16 (72.7)39 (4.99)14 (15.1)3 (13.6)27 (3.45)0 (0)3 (13.6)	with POAG, PACG, PAC and PACS.Normal, NPACD(%)PACS, NPAC, N (%)PAC1153(100)136 (100)33 (100)21 (115)440 (38.2)17 (12.5)5 (15.2)0 (115)328 (28.5)46 (33.8)12 (36.4)5 (31.6)385 (33.4)73 (53.7)16 (48.5)16 (36.6)639 (55.4)95 (69.9)26 (78.8)13 (61.9)809 (79.3)93 (79.5)19 (63.3)12 (32.0)716 (91.6)79 (85.0)16 (72.7)11 (34.6)39 (4.99)14 (15.1)3 (13.6)1 (76.69)27 (3.45)0 (0)3 (13.6)1 (76.69)	Normal, N PACS, N PAC, N (%) PACed Total, N (%) PACS, N PAC, N (%) PACed Total, N 1153(100) 136 (100) 33 (100) 21 (100) 190 (100) 440 (38.2) 17 (12.5) 5 (15.2) 0 (100) 190 (100) 328 (28.5) 46 (33.8) 12 (36.4) 5 (300) 63 (33.2) 385 (33.4) 73 (53.7) 16 (48.5) 16 (21.6) 105 (55.3) 639 (55.4) 95 (69.9) 26 (78.8) 13 (61.00) 124 (75.6) 809 (79.3) 93 (79.5) 19 (63.3) 12 (32.0) 124 (75.6) 716 (91.6) 79 (85.0) 16 (72.7) 11 (34.4) 106 (82.8) 39 (4.99) 14 (15.1) 3 (13.6) 1 (26.6) 18 (14.1) 27 (3.45) 0 (0) 3 (13.6) 1 (26.6) 4 (3.13)

		BMJ Open		njopen- by cop		Р	Page
				mjopen-2020-040795 1 by copyright, incluc			
				40795 includi			_
PVI (%)	228 (19.8)	45 (33.3)	12 (36.4)		67 (35.5)	13 (44.8)	
CCT(µm)	541.7±33.2 5	535.5±33.4	542.9±29.8	550.4 5+2 8.9	538.4±32.5	542.5±35.2	
IOP (mmHg, SD)		15.1±2.88	14.8±4.25	19.4 <u>æ</u> 8:36	15.5±3.71	15.8±2.87	_
Abbreviations: PACD=Primary a	ngle closure disease, POAC	C=Primary or	ben angle glauc	oma, PA	rimary angle cl	losure	
glaucoma, PAC= Primary angle	closure, PACS= Primary an	igle closure ະ	suspect, BMI=Br	ody mas	ι, PVI=Presenti	ng visual	
impairment, CCT=central cornea				perieu and c			
				ded from http://bmjopen.bmj.com/ on June 13, 2025 rieur (ABES) nd data mining, Al training, and similar technologies			
				ı http SES) ninin			
				ig, Al			
				ıjope train			
				n.bm ling, i			
				j.com and s			
				imila			
				June r tech			
				13, hno			
				2025 ¿ logies			
				°, at			
				2025 at Agence logies.			
				at Agence 5.			
		23		at Agence 5.			
		23		at Agence 5.			
	For peer review only - http://br		· /sita/about/guideli	at Agence Bibliographique c ,			

1	
2	
2	
1	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 20 21 22 23 24 25 26 27 28 30 31 32 33 34 35 36 37	
10	
17	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
32	
31	
25	
22	
30	
3/	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
50 51	
52	
53	
54	
55	
56	
57	
58	
59	

Table 2 Distribution of Basic Characters Associated with Mortality at Baseline Examination.


Basic Factors	Died, N (%)	Alive, N (%)	P-value
Total number (%)	306 (100)	1066 (100)	
Age (%)			<0.001
50-59	23 (7.52)	443 (41.6)	
60-69	66 (21.6)	332 (31.1)	
+70	217 (70.9)	291 (27.3)	
Female (%)	147 (48.0)	634 (59.5)	<0.001
No more than middle school	155 (67.7)	800 (81.4)	<0.001
ncome less than 1000RMB	173 (83.2)	543 (71.7)	0.001
BMI (kg/m²)			0.009
Normal (18.5-30.0)	169 (85.8)	676 (91.5)	
Under weight (<18.5)	22 (11.2)	38 (5.14)	
Over weight (<u>></u> 30.0)	6 (3.05)	25 (3.38)	
lypertension (%)	111 (44.4)	407 (40.6)	0.277
Diabetes (%)	33 (13.2)	98 (9.79)	0.120
PVI (%)	120 (39.5)	188 (17.6)	<0.001
/CDR(mean±SD)	0.49±0.18	0.44±0.17	<0.001
CCT(µm)	540.3±35.3	541.5±32.5	0.582
· (r)			

technologies. angle closure suspect, BMI=Body mass index, PVI=Presenting visual impairment, VCDR vertical cup-to-disc ratio, CCT=central cornea thickness, IOP=Intraocular pressure.

				BMJ Open		mjopen-2020-040795 d by copyright, inclu		F	age 26 of 30
1 2 3 4 5 1 Table 3 Co.	x Proportional H	azards Mo	dels of ten-Year N	lortality Categorize	ed by Angl	dir o			
8	Participants,	Died, N	Mortality Rate,			н <mark>ह</mark> ्य भूर्ख्ने % С	I)		
9 10	Ν		%(95%CI)	Univariable	P-value	Age and de	P-value	Multivariable	P-
11 12				Univaliable	i value		i value	Adjusted†	value
1 <u>3</u> 14 Angle Status			Or .			st an			
15 16 Normal	1153	235	20.4 (18.1,22.8)	Reference [1]		Refere		Reference [1]	
¹⁷ 18 PAC	33	10	30.3 (15.6,48.7)	1.41(0.75,2.65)	0.284	1.27 (0. c , 39)	0.463	0.85 (0.37,1.94)	0.702
¹⁹ PACS	136	43	31.6 (23.9,40.1)	1.59(1.15,2.19)	0.005	1.32 (0.95,183)	0.099	1.27 (0.84,1.90)	0.253
²¹ ₂₂ PACG	21	10	47.6 (25.7,70.2)	2.63(1.40,4.95)	0.003	2.15 (1. 1 4, 4 04)	0.018	1.60 (0.70,3.61)	0.263
²³ ₂₄ PACD	190	63	33.2 (26.5,40.3)	1.74(1.32,2.30)	<0.001	1.46 (1. 4 0, 1 95)	0.009	1.25 (0.87,1.79)	0.221
25 (PAC+PACS+PACG 26 POAG	29	8	27.6 (12.7,47.2)	1.31(0.65,2.65)	0.449	0.74 (0.36,149)	0.395	0.70 (0.32,1.51)	0.359
27 28 Any glaucoma	50	18	36.0 (22.9,50.8)	1.85(1.15,2.97)	0.012		0.505	0.96 (0.54,1.71)	
²⁹ (PACG+POAG) ³⁰					0.012	titech	0.000		
31 2 Abbreviatio	ns: PAC= Prim	ary angle	closure, PACS=	Primary angle clo	sure susp	pect, PAC 💈 👸 rimar	y angle cl	osure glaucoma,	
	nary angle closu	re disease	e, POAG=Primary o	open angle glauco	ma, HR=F	Hazard ratio, Clarent	idence inte	rval.	
 34 35 36 4 † Adjusted 	for age, gender,	education	, income, body ma	iss index, presenti	ng visual i	mpairment, history of	diabetes a	and hypertension.	
37 38 5						Bibl			
39				25		iogra			
40 41						phiq			
42 43		Fc	or peer review only - htt	p://bmiopen.bmi.com/	ite/about/o	uidelines.xhtml			
44 45			- peer center only fitt			_			
46									

Pa	ge 27 of 30				BMJ Open		mjopen-2020-0 1 by copyright,			
1 2 3 4 5 6 7 8	1 2 Table 4 C	ox Proportional	Hazards	Models of ten-Year	Mortality Categori	zed by IOF)40795 on 7 O including for			
9 10		Participants,	Died,	Mortality				CI)		
11 12 13 14 15		Ν	Ν	Rate, %(95%Cl)	Univariable	P-value	Age and Generation	P-value	Multivariable Adjusted†	P-value
16	IOP						ed fro eur (A 1 data			
17 18	Unit increase	-	-	-	1.02(0.99,1.05)	0.580	1.02 (0.99)	0.262	1.02 (0.99,1.05)	0.203
19 20	10~21	1267	272	21.5(19.2,23.8)	Reference [1]		Reference [Reference [1]	
21 22	<10	43	12	27.9(15.3,43.7)	1.32(0.74,2.35)	0.349	1.16 (0.68 at	0.680	0.91 (0.44,1.89)	0.798
23 24	>21mmHg	50	14	28.0(16.2,42.5)	1.34(0.78,2.28)	0.291	0.97 (0.48 1.9 7)	0.584	0.97 (0.49,1.91)	0.935
25 26	VCDR						and s			
27 28	Unit increase	-	-	-	3.86(2.05,7.26)	<0.001	1.76 (0.94 3.3)	0.076	1.59 (0.74,3.46)	0.238
29	<u><</u> 0.3	453	68	15.0(11.8,18.6)	Reference [1]		Reference [1]		Reference [1]	
30 31	>0.3	867	209	24.1(21.3,27.1)	1.71(1.30,2.25)	<0.001	1.53 (1.16 2.0 1)	0.002	1.60 (1.11,2.33)	0.011
32 33	3 Abbreviat	ions: IOP=Intrao	ocular pre	essure, VCDR=Verti	cal cup disc ration	, HR= Haza	ard ratio, CI=congride	nce interva	al.	
34 35 36 37	4 † Adjusted	d for age, gende	er, educa	tion, income, body r	nass index, preser	iting visual	impairment, history	of diabete	s and hypertension	1.
38 39 40 41					26		ibliographique			
42 43 44 45 46				For peer review only - I	http://bmjopen.bmj.con	n/site/about/o	đ			

BMJ Open: first published as 10.1136/bmjopen-2020-040795 on 7 October 2021. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.



288x172mm (150 x 150 DPI)

				BMJ Open		mjopen-2020-040795 1 by copyright, includ			
Supplement						ized by Ve Dre of dif	ferent cut-o	off.	
	Participants, N	Died, N	Mortality Rate, %(95%Cl)	Univariable	HR (95% (P-value	Age and Gender	P-value	Multivariable Adjusted†	P-
VCDR						Down I to tex			
<u><</u> 0.5	1012	197	19.5(17.1,22.0)	Reference [1]		Reference [1]		Reference [1]	
>0.5	308	80	26.0(21.2,31.2)	1.37(1.06,1.78)	0.016	1.10 (0.9	0.500	1.11 (0.82,1.51)	0
VCDR						http:// ES) . lining,			
<0.7	1160	229	19.7(17.5,22.2)	Reference [1]		Refere [1]		Reference [1]	
<u>></u> 0.7	160	48	30.0(23.0,37.7)	1.62(1.18,2.20)	0.003	1.16 (0, 34, 59)	0.367	1.15 (0.80,1.67)	C
						d ratio, Cl=confidence pairment, this 13, 2025 at Agence Bibliographique de delines.xhtml		nd hypertension	
		Fo	or peer review only - htt	o://bmjopen.bmj.com/s	ite/about/gui	delines.xhtml			

Page 29 of 30

3 4

24

		BMJ Open BMJ Open-2020	Page
		Figure 2007 (v4) Statement—Checklist of items that should be included in reports of <i>cogort studies</i> 일 경	
Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract ឆ្លូ ញថ្ងឺ	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3-4
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported 5 3	6
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure,	7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifier Give diagnostic criteria, if	7-9
Data sources/	8*	For each variable of interest, give sources of data and details of methods of assessment (meagurement). Describe	7-9
measurement		comparability of assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	7-9
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which gougings were chosen and why	8,10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	10
		(b) Describe any methods used to examine subgroups and interactions	10
		(c) Explain how missing data were addressed and the second	10
		(d) If applicable, explain how loss to follow-up was addressed	
		(e) Describe any sensitivity analyses	
Results			

 nique

del

30		BMJ Open by copyrigh	
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, exany and for eligibility, confirmed	10-11
		eligible, included in the study, completing follow-up, and analysed E g (b) Give reasons for non-participation at each stage g g	11
		(c) Consider use of a flow diagram	11
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information အကြားမှာ တို confounders	11
		(b) Indicate number of participants with missing data for each variable of interest	10-11
		(c) Summarise follow-up time (eg, average and total amount)	11
Outcome data	15*	Report numbers of outcome events or summary measures over time	11
Main results	16	(<i>a</i>) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precedent of the strength of the strengt of the strength of the strength of the strength of the st	11-12
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	12
Discussion		g, Al	
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of a glyses, results from similar studies, and other relevant evidence	12-16
Generalisability	21	Discuss the generalisability (external validity) of the study results	12-16
Other information		echi echi	
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	2

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in controls in case-control studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published exan less of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine 👼 rg/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.spobe-statement.org.

BMJ Open

Association of Glaucoma with Ten-Year Mortality in a Population-based Longitudinal Study in Urban Southern China: The Liwan Eye Study

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-040795.R2
Article Type:	Original research
Date Submitted by the Author:	01-Nov-2020
Complete List of Authors:	Wang, Langhua; Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology Zhu, Zhuoting; Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology Huang, Wenyong; Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology Scheetz, Jane; Centre for Eye Research Australia Ltd He, Mingguang; Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology
Primary Subject Heading :	Ophthalmology
Secondary Subject Heading:	Epidemiology, Public health
Keywords:	Glaucoma < OPHTHALMOLOGY, EPIDEMIOLOGY, PUBLIC HEALTH, OPHTHALMOLOGY

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



2		
3 4	1	Association of Glaucoma with Ten-Year Mortality in a Population-based
5	2	Longitudinal Study in Urban Southern China: The Liwan Eye Study
6 7	2	
8 9	3	
10 11 12	4	Running tilt: Glaucoma and mortality
12 13 14	5	Research question: The association between glaucoma and ten-year
15 16	6	mortality in an adult population in China
17 18 19	7	Study design: Population-based cohort study
20 21	8	
22 23 24	9	Authors
25 26 27	10	Lanhua Wang MD, PhD ^{1*}
28 29 30	11	Zhuoting Zhu MD, PhD ^{1,2*}
31 32	12	Wenyong Huang MD, PhD ¹
33 34 35	13	Jane Scheetz, PhD ³
36 37	14	Mingguang He MD, PhD ¹
38 39 40	15	
41 42 43	16	*These authors contributed equally to this study.
44 45	17	
46 47 48	18	Institutions
49 50	19	1. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center,
51 52 53	20	Sun Yat-sen University, Guangzhou, China
54	21	2. Department of Ophthalmology, Guangdong Eye Institute, Guangdong
55 56 57	22	Provincial People's Hospital, Guangdong Academy of Medical Sciences,
57 58 59	23	Guangzhou, China
60		1

BMJ Open

2		
3 4	1	3. Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital,
5	h	Melbourne, Australia
6 7	2	Melbourne, Australia
8	3	
9	3	
10	4	Financial support: Supported by the Fundamental Research Funds of the
11 12	4	Thancial Support. Supported by the Fundamental Research Funds of the
13	5	State Key Laboratory of Ophthalmology, National Natural Science Foundation
14 15	6	of China (81420108008 and 81570843H1204), and Science and Technology
16	0	
17	7	Planning Project of Guangdong Province, China 2013B20400003.
18		
19 20	8	Conflict of Interest: The authors have no financial or other conflicts of
21	9	interest concerning this study.
22		
23 24	10	Data availability: Data are available upon reasonable request.
25		
26	11	Correspondence:
27 28		
29	12	Prof Mingguang He
30		
31 32	13	Sun Yat-sen University
33		
34	14	Zhongshan Ophthalmic Center
35 36		
37	15	State Key Laboratory of Ophthalmology, ,
38		
39 40	16	Guangzhou 510060, People's Republic of China
41		
42	17	Email: mingguanghe@gmail.com
43 44		
45	18	
46	10	
47 48	19	
49	20	Word count: Abstract: 202: Whole paper: 2007
50	20	Word count: Abstract:293; Whole paper: 3097.
51 52	21	Tables: 4 Figure: 2
53	21	Tables: 4 Figure: 2
54	22	Supplement Table:1
55 56	<i>LL</i>	
57	23	
58	23	
59 60		2

1 Abstract

Objectives: To investigate the association between glaucoma and ten-year
 mortality rate in an adult population in China.

Design: Population-based cohort study.

Setting: The Liwan Eye Study, China.

6 Participants: 1405 baseline participants aged 50 years and older were invited
7 to attend a ten-year follow-up examination.

Primary and secondary outcome measures: The International Society of Geographic and Epidemiologic Ophthalmology criteria was used to define glaucoma. Detailed information of mortality was confirmed using the Chinese Centre for Disease Control and Prevention. Presenting visual impairment (PVI) was defined as a presenting visual acuity of less than 20/40 in the better-seeing eye. The ten-year mortality rates were compared using the log-rank test. Cox proportional hazards regression models were used to investigate the association between glaucoma and mortality. **Results:** A total of 1372(97.7%) participants with available gonioscopic data were included in the analysis. Of these, 136(9.9%), 33(2.4%) and 21(1.5%) participants had primary angle closure suspect (PACS), primary angle closure (PAC) and primary angle closure glaucoma (PACG), and 29(2.1%) had primary open angle glaucoma (POAG). After ten years, 306 (22.3%) participants were deceased. The ten-year mortality was significantly associated with PACG (HR, 2.15,95%CI:1.14-4.04,P=0.018) but not associated with PAC (HR,1.27,95%CI:0.67-2.39, P=0.463), PACS (HR,1.32,95%CI:0.95-1.83, P=0.099) and POAG (HR, 0.74, 95%CI:0.36-1.49, P=0.395) when age and gender were adjusted for. This association was no

longer statistically significant (HR,1.60, 95%CI:0.70-3.61, P=0.263) when co-

27 variables, such as income, education, body mass index, PVI, history of

BMJ Open

2		
3 4	1	diabetes and hypertension, were adjusted for. Larger vertical cup-to-disc ratio
5		
6	2	(VCDR>0.30) was only a significant risk factor in multivariable analysis (HR,
7 8 9	3	1.60,95%CI:1.11-2.33, P=0.011).
10 11	4	Conclusions: PACG was significantly associated with higher long-term
12 13	5	mortality but this association was likely to be confounded by other systemic
14 15	6	risk factors. VCDR>0.3 was the only independent predictor, implying that it
16 17	7	may be a marker of ageing and frailty.
18 19 20	8	
20 21 22	9	Patient and Public Involvement Statement: No patients and public were
23	10	involved in the design and process of this study.
24 25		
26	11	Key words: Glaucoma; Mortality; China; Cox proportional hazards regression
27 28	12	model
29 30 31	13	
32 33	14	
34	14	
35 36	15	
37 38	16	
39	16	
40 41 42	17	
43 44	18	
45 46 47	19	
48 49 50	20	
51 52	21	
53 54 55	22	
56 57 58 59 60	23	4

1		
2		
3	1	
4	1	
5		
6	2	
7		
8	2	Otrepathe and limitations of this study.
9	3	Strengths and limitations of this study
10		
11	4	1. The present study was a population-based cohort study which utilized a
12		
13 14	5	standardized study protocol
14		
16	(2. The International Society of Coographic and Enidomiologic Ophthalmology
17	6	2. The International Society of Geographic and Epidemiologic Ophthalmology
18	7	criteria was used to define glaucoma
19	/	
20		
21	8	3. Study limitations include the following: 1) small number of patients with
22		
23	9	glaucoma;2) several important confounding factors, such as smoking status
24	10	were not evallable
25	10	were not available.
26		
27	11	
28		
29	10	
30	12	were not available.
31		
32 33	13	
34		
35	14	
36	14	
37		
38	15	
39		
40	16	
41	10	
42		
43	17	
44		
45	18	
46	10	
47		
48	19	
49		
50	20	
51 52	20	
52 53		
53 54	21	
54 55		
56	22	
57		
58		
59	23	
60		5

1 Introduction

Glaucoma is one of the leading causes of irreversible visual impairment (VI) and blindness worldwide, affecting approximately 64.3 million people .¹ It has been estimated that the number of people diagnosed with glaucoma in China was 13.1 million in 2015, more than half of which were diagnosed with primary angle closure glaucoma(PACG).² With the current ageing population, this number is expected to reach 15.2 million by 2050.²

In addition to its impact on vision and quality of life, some studies have reported that patients with glaucoma have higher rates of mortality,³⁻⁶ while others found no association,⁷⁻¹⁸ Disparate findings have led to controversies regarding the risk of premature mortality of patients with glaucoma. Similarly, inconsistent evidence has been observed regarding the association between levels of intraocular pressure (IOP), a well-established functional risk factor for glaucoma, and survival.^{14, 17, 18} The relationship between mortality and vertical cup-to-disc ratio (VCDR), a robust structural indicator of glaucomatous loss of the neuroretinal rim, has been exclusively investigated in the Andhra Pradesh Eye Disease Study (APEDS), implying that nerve fiber loss may be a marker of ageing and frailty.⁷ Of note, previous studies, mainly in white and black populations, investigated the relationship between primary open angle glaucoma (POAG), elevated IOP and long-term survival.^{8-10, 12, 14, 15, 18, 19} In comparison, few studies have been conducted in Asian populations.^{3, 4, 7, 11, 13,} ¹⁶ Furthermore, dominant subtypes, clinical presentations and the underlying pathogenesis of glaucoma in Asian populations vary from those in white and black populations.^{20, 21} A better understanding of the relationship between different subtypes of glaucoma (POAG and primary angle closure disease (PACD)), level of IOP, VCDR and risk of mortality may provide insights into the potential mechanisms and clinical management of glaucoma.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

1 Therefore, the aim of this study was to explore the relationship between

different types of glaucoma, level of IOP, VCDR and ten-year mortality in an
 adult population in southern urban China.

Methods

6 Study Population

A detailed description of the methodology utilized in the Liwan Eye Study has been described previously.²² Briefly, the Liwan Eye Study was a population-based cohort study that commenced in 2003 with a five-year follow-up (2008 to 2009) and a ten-year follow-up (2013), both follow-up examinations followed an identical protocol. At baseline, 75.4% (1405 of 1864) of eligible participants underwent a comprehensive eye examination and a questionnaire regarding income, education, and medical history. All participants in the baseline study were invited back for the five- and ten-year follow-up examinations. A total of 924 participants (75.0% of survivors, 79.1% of eligible participants) returned for the five-year examination and 791 (73.8% of survivors, 86.2% of eligible participants) for the ten-year examination.

Ethical approval for the study was obtained from the Zhongshan University Ethics Review Board, and the Research Governance Committee of Moorfields Eye Hospital, London. The study was conducted in accordance with the tenets of the World Medical Association's Declaration of Helsinki. Written informed consent was obtained from all participants.

25 Study procedure

26 All participants had their presenting visual acuity (PVA) tested using an Early

Page 9 of 31

BMJ Open

Treatment Diabetic Retinopathy Study (ETDRS) vision chart whilst wearing their habitual refractive correction. Best-corrected visual acuity (BCVA) was measured for those with PVA \leq 20/40 in either eye. Presenting visual impairment (PVI) was defined as PVA less than 20/40 in the better-seeing eye. The IOP was measured before mydriasis by a handheld tonometer (Tonopen; Mentor, Norwell, Massachusetts, USA) with three consecutive measurements of an achieved standard error of <5%. Central cornea thickness (CCT) was evaluated using an ultrasound pachymetry (Echoscan US1800; Nidek, Corp). Height and weight were measured without shoes, using a standard calibrated scale. Body mass index (BMI) was calculated as the weight in kilograms divided by the square of the height in centimeters and was divided into three groups: underweight (BMI <18.5 kg/m²), normal to overweight (18.5 to 30 kg/m²), or obese (BMI \geq 30.0 kg/m²). Diabetes mellitus (DM) and hypertension were based on self-reported history of a diagnosis and/or previous medication use.

Slit-lamp examination (TopconSL-8Z, Tokyo, Japan) with a 78-diopter lens was used to identify abnormalities of the anterior segment and posterior segment by an experienced ophthalmologist (MH). Detailed information of the gonioscopic examination in the Liwan Eye Study has been described previously.²² Briefly, all participants underwent slit lamp based static and dynamic gonioscopy with a Goldmann-type, one-mirror lens (Haag Streit, Bern, Switzerland) at 25x magnification by the same experienced specialist-trained ophthalmologist (MH). Narrow angle and open angle were stratified by status of the iris insertion and recorded using five categories by the Shaffer system. ²³According to the International Society of Geographical and Epidemiological Ophthalmology (ISGEO) classification, primary angle closure suspect (PACS) was defined as simply an angle in which ≥270° of the

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

> pigmented trabecular meshwork cannot be seen without evidence of trabecular obstruction and glaucomatous damage. Primary angle closure (PAC) was defined as eyes with PACS and features of peripheral anterior synechiae, elevated IOP, iris wholing, or excessive pigment deposition on the trabecular surface, but no evidence of glaucomatous damage. Primary angle closure glaucoma (PACG) was defined as eyes with PAC and evidence of glaucomatous damage. Participants with PACS, PAC or PACG were grouped as PACD.

The optic disc was assessed using a 78-D lens at 16x magnification. The VCDR was used as key indicator of structural glaucomatous change. Visual field (VF) assessment was performed in those with a VCDR of >0.7(97.5th percentile of the Liwan Eye Study) in either eye, VCDR asymmetry >0.2 or IOP of >21 mm Hg on a subsequent day. The definition of glaucoma was based on three levels of evidence using ISGEO criteria. The division of POAG and PACG was based on the gonioscopic results of narrow angle or open angle. If glaucoma status or VCDR were observed in both eyes, the eye with more severe status or larger VCDR value was used in the analysis.

Detailed data from the Chinese Centre for Disease Control and Prevention (CDC) were used to confirm the mortality of participants during the ten-year follow-up period. After providing the CDC with a list of names, age, year of birth, gender and latest address for the participants suspected of having passed away, based on which researchers at the CDC provided a corresponding list of "matched" deaths with dates and causes. The causes of death recorded by the CDC were documented on the death certificates using the International Classification of Diseases, Ninth Revision.

Page 11 of 31

BMJ Open

1 Statistical analysis

All statistical analyses were performed using Stata (ver. 10.0; Stata Corp. College Station, TX). The student's t-test was used to compare continuous variables, while Pearson chi squire or Fisher's exact test for the comparison of categorical data. Survival times were calculated for each participant from the date of baseline examinations to the date of death or April 30, 2014. Univariable and multivariable Cox proportional hazard regression models were used to test the associations between mortality and baseline PACS, PAC, PACG, POAG, IOP and VCDR after adjusting for baseline characteristics of age, gender, education level, family income, history of diabetes and hypertension and PVI. These confounding factors were chosen based on the previous evidence. 24-28 The significant association between PVI and long-term survival in this population have been reported previously.²⁹ Analysis of IOP and VCDR were based on both continuous and categorical level. IOP was divided into three categorical groups: 10-21mmHg (reference group), <10mmHg and >21 mmHg. The lowest guartile of VCDR (<0.3), the third quartile of VCDR in this population (<0.5) and VCDR of < 0.7 (97.5th percentile of the Liwan Eye Study) were used as the reference group to assess associations of different VCDR cut-offs with long-term survival. Hazard ratios (HR) and 95% confidence intervals (CI) were given. A proportional hazard test was used to check the assumption of cox proportional hazards model, and the log-rank test was used to compare different groups with respect to their survival distributions.

Results

Of the 1405 participants at baseline, 33 were excluded (30 without

27 gonioscopic data, 3 with secondary glaucoma and 1 with un-classified reason

du to cataract surgery), leaving 1372 participants with complete data available for analysis. Among the 1372 participants, the prevalence of PACS, PAC, PACG, and POAG was 9.9% (136 participants), 2.4% (33 participants), 1.5% (21 participants), and 2.1% (29 participants), respectively (Figure 1). Compared to the 1153 normal participants, those with PACD were more likely to be older (P<0.001), female (P=0.001), underweight (P<0.001), of a lower level of family income (P=0.005) and have a higher proportion of PVI (P<0.001). There were no statistically significant differences between groups in terms of level of education, hypertension, diabetes, CCT and IOP. Compared to the 1,153 normal participants, those with POAG tended to be older (P=0.003), male (P=0.003) and had a higher proportion of PVI (P=0.001) (Table 1). By the end of April 2014 (median follow-up length: 9.38 years; range: 0.15-10.4), 306 (22.3%) of the 1,372 participants passed away, 294 (21.4%) did not return for re-examination because they declined participation (126), relocated (122) or were uncontactable (41), leaving 777(56.6%) at the ten-year follow-up examination. Detailed follow-up information can be found in Figure 1. Those who passed away tended to be older (P<0.001), male (P<0.001), have a lower level of educational attainment (P=0.001), lower family income (P<0.001), higher proportion of PVI (P<0.001), larger VCDR (P<0.001) and be underweight (P=0.009). The medical history of hypertension and diabetes, CCT and mean IOP value were similar between the two groups (Table 2). Among the 1153 participants without PACD or POAG, 235 (20.4%, 95%CI=18.1, 22.8%) passed away during the ten-year follow up period. The ten-year mortality rate of the 1153 participants was significantly lower than

	1	those with PACS (43/136, 31.6%, 95%CI= 23.9, 40.1%), PAC (10/33, 30.3%,
	2	95%CI= 15.6, 48.7%), PACG (10/21, 47.6%, 95%CI=25.7, 70.2%), and POAG
	3	(8/29, 27.6%, 95%CI= 12.7, 47.2%). The Kaplan-Meir survival estimates for
I	4	types of glaucoma and mortality were displayed in Figure2. The age and
	5	gender adjusted cox proportional hazards model showed that the presence of
	6	PACG (HR=2.15, 95% CI=1.14, 4.04), PACD (HR=1.46, 95% CI=1.10, 1.95)
	7	and a VCDR of more than 0.3 (HR=1.53, 95% CI=1.16, 2.01) were
	8	significantly associated with a higher risk of mortality. No association was
1	9	found between mortality and PACS, PAC, POAG and level of IOP. After
	10	adjusting for age, gender, education, income, history of diabetes and
	11	hypertension, BMI and PVI, the significant association between VCDR of
	12	more than 0.3 and poorer survival rate was still observed (HR=1.60, 95%
	13	CI=1.11, 2.33) (Table 3 and Table 4). A strong association between ten year
	14	mortality and a VCDR>0.5 (HR=1.37, 95% CI=1.06, 1.78) and VCDR <u>></u> 0.7
	15	(HR=1.62, 95% CI=1.18, 2.20) were found in the univariable analysis,
	16	whereas these associations disappeared after adjusting for confounders (all
	17	P>0.05, Supplement Table 1).
	18	P>0.05, Supplement Table 1).
	19	Discussion
	20	In this population-based cohort study, we found a higher crude mortality rate
	21	among patients with POAG and any form of PACD (ranging from 7.2% to
1	22	27.2%). However, this difference was not replicated after multivariable
1	23	confounders were adjusted for. Level of IOP was not significantly associated
1	24	with an increased risk of ten-year mortality in the multivariable model, while

VCDR of more than 0.3 was an independent predictor of long-term poor
survival.

Page 14 of 31

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

Controversy still exists around the association between POAG and the increased risk of mortality.^{3-10, 12, 14-16, 18, 19} Almost 50 years ago, Egge et al found a decreased 30-year survival rate for patients with glaucoma in Norway. This finding was more pronounced among men using acetazolamide.⁶ Results of the National Health Interview Survey (NHIS) 1986-1994 also supported the finding that glaucoma was related to an increased risk of all-cause and cardiovascular disease mortality among adults residing in the United States.⁵ However, the glaucoma-mortality association in the NHIS is likely to have been impacted by recall bias (self-reported definition of glaucoma), misclassification error and underestimation of glaucoma cases. Furthermore, the diagnostic methods, definition and treatments of glaucoma have changed over the past five decades, making its findings less generalizable to today's glaucoma patients. More recent studies are in favor of the finding that POAG is not significantly associated with long-term survival.^{3, 4,7-10, 12, 14-16, 18} The non-significant relationship in these studies are in agreement with the findings of our study. Differences in ethnicity, age distribution, study design, length of follow-up, definition of glaucoma, and confounding variables adjusted for in the multivariate model may explain the inconsistent results between studies. Alternatively, the small number of patients with POAG in the current study (n=29) may also explain the lack of association between POAG and ten-year mortality. However, a recent meta-analysis of observational studies¹⁷ supported the finding of a non-significant relationship between POAG and risk of mortality.

Few studies have explored the relationship between different types of PACD and mortality. Similar to the current study, previously investigations have reported that the presence of PACD was not an independent risk factor for allcause mortality.^{7, 11, 13, 16} Thus far, only five-year data from the Beijing Eye

Page 15 of 31

BMJ Open

Study has reported that the presence of PACG was related to an increased risk of mortality using multivariate analysis.^{3, 4} Interestingly, the ten-year data from the Beijing Eye Study found that mortality was not significantly associated with PACG.¹⁶ Neither the Tanjong Pagar Study¹¹ or the Singapore Malay Eye Study (SiMES)¹³ found significantly reduced survival among those with glaucoma. In the current study, we found that PACG was significantly associated with ten-year mortality in the age and gender adjusted model, but this significant association was not found in the multivariate model. This is likely due to other confounding factors not accounted for and the relatively small sample size.

The results of this study found a non-significant association between the level of IOP and ten-year mortality rate. Previous reports on the relationship between all-cause mortality and elevated IOP have been inconsistent.7, 14, 18, 19 Excess all-cause mortality associated with ocular hypertension was found in the Barbados Eye Study and the Framingham Study,¹⁸ while the APEDS⁷ and a Swedish study¹⁴ found no statistically significant association between elevated IOP and mortality risk. The APEDS was the only study to explore the association between VCDR and all-cause mortality. Consistent with the APEDS's finding that increasing VCDR was a predictor of ten-year mortality,⁷ we also reported a significantly increased risk of mortality among participants with VCDR of more than 0.3. Considering that previous studies have indicated that global retinal nerve fiber layer decreased significantly with age and larger VCDR,^{30, 31} one can speculate that the potential mechanism underlying the VCDR-mortality association may be caused by retinal nerve fiber layer thinning, a marker of ageing and frailty. Furthermore, the close relationship between neurodegenerative diseases (e.g., Alzheimer's disease and Parkinson's disease) and glaucoma, and the strong link between retinal nerve

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

> fiber layer thinning and brain pathology adds weight to our speculation.³²⁻³⁵ The non-significant association of other cut-offs, or linear of VCDR with all-cause mortality after adjusting for confounders might be due to the small sample size or non-linear relationship in our study. Alternatively, we can only speculate that VCDR of less than 0.3 (i.e., sufficient retinal nerve fibre layer) which represent physiological process of aging or neurodegeneration might be the threshold for better survival. Further studies with a larger study sample are needed to investigate the association between VCDR, retinal nerve fiber layer thickness and mortality.

Even though the mechanisms underlying the association between glaucoma/ocular hypertension-mortality is still unclear, it has been speculated that increased risk of mortality among patients with glaucoma or ocular hypertension might be caused by IOP-lowering treatment. Glaucoma-mortality association has been found to be more pronounced among men using acetazolamide.⁶ The excess mortality linked to timolol maleate treatment for POAG found in the Barbados Eye Study¹⁸ was also parallel to the hypothesis of this study. In the BMES, a dose-dependent pattern was observed in the association between duration of timolol maleate use and increased risk of cardiovascular disease mortality. In addition, previous studies verified the adverse effects of IOP-lowering treatments, including congestive heart failure, raised blood pressure and adverse respiratory effects.^{36, 37} However, the dose-dependent pattern observed in the BMES may be due to detection bias. Approximately 50-90% of glaucoma patients remain undiagnosed.^{7, 38} Participants in poorer health are more likely to access health care services and therefore have their glaucoma diagnosed and treated. The suggestion that detection bias is a cause of variable findings was further verified by the similar mortality rates between treated and untreated glaucoma patients in

Page 17 of 31

 BMJ Open

multicenter randomized glaucoma treatment trials (Early Manifest Glaucoma
Trial and Ocular Hypertension Treatment Study) and the observational
Rotterdam study.³⁹⁻⁴¹ Even these two studies concluded that the use of
glaucoma medications was associated with a reduced risk of mortality.^{42, 43}
Future investigations are required to assess this association further.

The strengths of the present study included the population-based study design, high participation rate, long-term follow-up, and standardized definition of glaucoma used. Of note, the present study was limited by the following points. Firstly, the small number of patients with glaucoma may explain the non-significant association between different types of glaucoma and mortality. Second, several important confounding factors, such as smoking status were not available in the present study. Nevertheless, the additional adjustment for these important confounding factors may further attenuate the magnitude of statistical significance and again verify the robustness of our results. Third, lack of data on the causes of death prevented the possibility of exploring the association between glaucoma and specific-cause mortality. Previous studies have reported a significant association between glaucoma and cardiovascular disease mortality.^{5, 44} Fourthly, the fact that only participants with suspect glaucoma (VCDR of >0.7 in either eye (97.5th percentile of the Liwan Eye Study population), VCDR asymmetry >0.2 or IOP of >21 mm Hg) underwent VF assessment may underestimate the prevalence of glaucoma because participants with early glaucomatous changes may be missed. However, previous ocular history and IOP measurements were collected for each participant, possibly lowering the risk of underestimation. Fifthly, the relationship between changes in glaucoma related parameters and long-term survival were unavailable due to insufficient data and limited follow-up times. Finally, we did not collect information on utilization of IOP-lowering treatment.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Further studies are required to investigate the relationship between IOP lowering treatment and long-term survival.

In conclusion, our findings suggest there is a higher level of crude mortality among patients with POAG, PACS or PAC. However, this difference was unable to be replicated after multivariable confounders were adjusted for. PACG was significantly associated with ten-year mortality in the age and gender adjusted model, but this significant association disappeared in the multivariable model. Level of IOP was not significantly associated with increased risk of ten-year mortality, while VCDR of more than 0.3 was an independent predictor of long-term survival. Further studies are needed to confirm these findings and to explore the association between different subtypes and treatments of glaucoma with long-term survival.

16 Acknowledgement:

Author Contributions: Study conception and design (LW, ZZ, MH); analysis and interpretation (LW, ZZ); writing of the article (LW, ZZ); critical revision of the article (WH, JS, MH); data collection (LW, ZZ, WH); administrative,

el.ez

21 technical or logistic support (JS, MH).

2		
3	1	Reference
4	1	Relefence
5 6	2	1. Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. The British journal of
7	3	ophthalmology 2012;96:614-618.
8	4	 Song P, Wang J, Bucan K, Theodoratou E, Rudan I, Chan KY. National and subnational
9 10	5	prevalence and burden of glaucoma in China: A systematic analysis. <i>Journal of global health</i>
10	6	2017;7:020705.
12	7	3. Xu L, Wang YX, Jonas JB. Glaucoma and mortality in the Beijing Eye Study. <i>Eye</i> 2008;22:434-
13	8	438.
14 15	9	4. Xu L, Wang YX, Wang J, Jonas JJ. Mortality and ocular diseases: the Beijing Eye Study.
16	10	Ophthalmology 2009;116:732-738.
17	11	 Lee DJ, Gomez-Marin O, Lam BL, Zheng DD. Glaucoma and survival: the National Health
18 19	12	Interview Survey 1986-1994. Ophthalmology 2003;110:1476-1483.
20	12	 Egge K, Zahl PH. Survival of glaucoma patients. Acta ophthalmologica Scandinavica
21	13	1999;77:397-401.
22	14	 Khanna RC, Murthy GVS, Giridhar P, et al. Glaucoma-associated long-term mortality in a rural
23 24	15	cohort from India: the Andhra Pradesh Eye Disease Study. <i>The British journal of ophthalmology</i>
25	10	2018;102:1477-1482.
26	17	 Sundqvist J, Ekstrom C. Open-angle glaucoma and mortality: A long-term follow-up study. <i>Acta</i>
27 28	18	
29	20	ophthalmologica 2018;96:e1038-e1039.
30		9. Borger PH, van Leeuwen R, Hulsman CA, et al. Is there a direct association between age-related
31	21	eye diseases and mortality? The Rotterdam Study. <i>Ophthalmology</i> 2003;110:1292-1296.
32 33	22	10. Cugati S, Cumming RG, Smith W, Burlutsky G, Mitchell P, Wang JJ. Visual impairment, age-
34	23	related macular degeneration, cataract, and long-term mortality: the Blue Mountains Eye Study.
35	24	Archives of ophthalmology 2007;125:917-924.
36 37	25 26	11. Foong AW, Fong CW, Wong TY, Saw SM, Heng D, Foster PJ. Visual acuity and mortality in a
38	26 27	chinese population. The Tanjong Pagar Study. <i>Ophthalmology</i> 2008;115:802-807.
39	27	12. McCarty CA, Nanjan MB, Taylor HR. Vision impairment predicts 5 year mortality. <i>The British</i>
40 41	28	journal of ophthalmology 2001;85:322-326.
41 42	29 20	13. Siantar RG, Cheng CY, Gemmy Cheung CM, et al. Impact of Visual Impairment and Eye
43	30 21	diseases on Mortality: the Singapore Malay Eye Study (SiMES). <i>Scientific reports</i> 2015;5:16304.
44 45	31	14. Grodum K, Heijl A, Bengtsson B. Glaucoma and mortality. <i>Graefe's archive for clinical and</i>
45 46	32	experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle $Ortethelmederie 2004;242;207,401$
47	33	<i>Ophthalmologie</i> 2004;242:397-401.
48	34	15. Knudtson MD, Klein BE, Klein R. Age-related eye disease, visual impairment, and survival: the
49 50	35	Beaver Dam Eye Study. Archives of ophthalmology 2006;124:243-249.
50 51	36	16. Wang YX, Zhang JS, You QS, Xu L, Jonas JB. Ocular diseases and 10-year mortality: the Beijing
52	37	Eye Study 2001/2011. Acta ophthalmologica 2014;92:e424-428.
53	38	17. Akbari M, Akbari S, Pasquale LR. The association of primary open-angle glaucoma with
54 55	39	mortality: a meta-analysis of observational studies. <i>Archives of ophthalmology</i> 2009;127:204-210.
56	40	18. Wu SY, Nemesure B, Hennis A, et al. Open-angle glaucoma and mortality: The Barbados Eye
57	41	Studies. Archives of ophthalmology 2008;126:365-370.
58 59	42	19. Hiller R, Podgor MJ, Sperduto RD, Wilson PW, Chew EY, D'Agostino RB. High intraocular
59 60		18
-		

3	1	pressure and survival: the Framingham Studies. American journal of ophthalmology 1999;128:440-445.
4	2	 Flammer J, Orgul S, Costa VP, et al. The impact of ocular blood flow in glaucoma. <i>Progress in</i>
5		
6 7	3	retinal and eye research 2002;21:359-393.
8	4	21. Yanagi M, Kawasaki R, Wang JJ, Wong TY, Crowston J, Kiuchi Y. Vascular risk factors in
9	5	glaucoma: a review. Clinical & experimental ophthalmology 2011;39:252-258.
10	6	22. He M, Foster PJ, Ge J, et al. Prevalence and clinical characteristics of glaucoma in adult Chinese:
11	7	a population-based study in Liwan District, Guangzhou. Investigative ophthalmology & visual science
12 13	8	2006;47:2782-2788.
13	9	23. Shaffer RN. Operating room gonioscopy in angle-closure glaucoma surgery. AMA archives of
15	10	ophthalmology 1958;59:532-535.
16	11	24. Wade KH, Carslake D, Sattar N, Davey Smith G, Timpson NJ. BMI and Mortality in UK
17	12	Biobank: Revised Estimates Using Mendelian Randomization. Obesity 2018;26:1796-1806.
18 19	13	25. Christ SL, Zheng DD, Swenor BK, et al. Longitudinal relationships among visual acuity, daily
20	13	functional status, and mortality: the Salisbury Eye Evaluation Study. <i>JAMA ophthalmology</i>
21	15	2014;132:1400-1406.
22		
23 24	16	26. Lee EY, Lee YH, Yi SW, Shin SA, Yi JJ. BMI and All-Cause Mortality in Normoglycemia,
24 25	17	Impaired Fasting Glucose, Newly Diagnosed Diabetes, and Prevalent Diabetes: A Cohort Study.
26	18	<i>Diabetes care</i> 2017;40:1026-1033.
27	19	27. Spoerri A, Schmidlin K, Richter M, Egger M, Clough-Gorr KM, Swiss National C. Individual and
28	20	spousal education, mortality and life expectancy in Switzerland: a national cohort study. Journal of
29 30	21	epidemiology and community health 2014;68:804-810.
31	22	28. Argulian E. Hypertension and mortality in the elderly: further insights. JAMA internal medicine
32	23	2013;173:325.
33	24	29. Wang L, Zhu Z, Scheetz J, He M. Visual impairment and ten-year mortality: the Liwan Eye
34 35	25	Study. Eye 2020.
35 36	26	30. Wang YX, Pan Z, Zhao L, You QS, Xu L, Jonas JB. Retinal nerve fiber layer thickness. The
37	27	Beijing Eye Study 2011. <i>PloS one</i> 2013;8:e66763.
38	28	31. Cheung CY, Chen D, Wong TY, et al. Determinants of quantitative optic nerve measurements
39	20 29	using spectral domain optical coherence tomography in a population-based sample of non-
40 41	30	glaucomatous subjects. <i>Investigative ophthalmology & visual science</i> 2011;52:9629-9635.
42	31	
43		32. Ramirez AI, de Hoz R, Salobrar-Garcia E, et al. The Role of Microglia in Retinal
44	32	Neurodegeneration: Alzheimer's Disease, Parkinson, and Glaucoma. Frontiers in aging neuroscience
45 46	33	2017;9:214.
40 47	34	33. Shi Z, Zheng H, Hu J, et al. Retinal Nerve Fiber Layer Thinning Is Associated With Brain
48	35	Atrophy: A Longitudinal Study in Nondemented Older Adults. Frontiers in aging neuroscience
49	36	2019;11:69.
50	37	34. Davis BM, Crawley L, Pahlitzsch M, Javaid F, Cordeiro MF. Glaucoma: the retina and beyond.
51 52	38	Acta neuropathologica 2016;132:807-826.
52 53	39	35. Kirbas S, Turkyilmaz K, Anlar O, Tufekci A, Durmus M. Retinal nerve fiber layer thickness in
54	40	patients with Alzheimer disease. Journal of neuro-ophthalmology : the official journal of the North
55	41	American Neuro-Ophthalmology Society 2013;33:58-61.
56 57	42	36. Frishman WH, Kowalski M, Nagnur S, Warshafsky S, Sica D. Cardiovascular considerations in
57 58	43	using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: focus
59	15	
60		19

1		
2 3		
5 4	1	on beta-adrenergic blockade. Heart disease 2001;3:386-397.
5	2	37. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an
б	3	antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding
7	4	bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure
8	5	Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. <i>Lancet</i> 2005;366:895-906.
9 10	6	38. Burr JM, Mowatt G, Hernandez R, et al. The clinical effectiveness and cost-effectiveness of
11	7	screening for open angle glaucoma: a systematic review and economic evaluation. <i>Health technology</i>
12		
13	8	assessment 2007;11:iii-iv, ix-x, 1-190.
14	9	39. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma
15 16	10	progression: results from the Early Manifest Glaucoma Trial. Archives of ophthalmology
17	11	2002;120:1268-1279.
18	12	40. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a
19	13	randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of
20	14	primary open-angle glaucoma. Archives of ophthalmology 2002;120:701-713; discussion 829-730.
21 22	15	41. Muskens RP, Wolfs RC, Witteman JC, et al. Topical beta-blockers and mortality. Ophthalmology
23	16	2008;115:2037-2043.
24	17	42. Glynn RJ, Knight EL, Levin R, Avorn J. Paradoxical relations of drug treatment with mortality in
25	18	older persons. <i>Epidemiology</i> 2001;12:682-689.
26		43. Stein JD, Newman-Casey PA, Niziol LM, Gillespie BW, Lichter PR, Musch DC. Association
27 28	20	between the use of glaucoma medications and mortality. <i>Archives of ophthalmology</i> 2010;128:235-240.
29		
30	21	44. Lee AJ, Wang JJ, Kifley A, Mitchell P. Open-angle glaucoma and cardiovascular mortality: the
31	22	Blue Mountains Eye Study. <i>Ophthalmology</i> 2006;113:1069-1076.
32 33	23	
33 34		
35	24	
36	25	
37	23	
38 39	26	
40		
41	27	
42	28	
43 44		
45	29	
46	30	
47	30	
48	31	
49 50		
51	32	
52	33	
53	55	
54 55	34	
55 56	25	
57	35	
58	36	
59		20
60		20

1		
2		
3	1	
4	1	
5	2	
6	2	
7	3	Figure legend:
8	5	rigure legend.
9	4	Figure1 Flow chart showing the enrollment and follow-ups of participants in
10	4	
11	5	the Liwan Eye Study
12		
13	6	Figure2 Kaplan-Meier curve of PACS, PAC, PACG, POAG, all types of
14	7	glaucoma, VCDR and mortality. A, PACS; B, PAC; C, PACG; D, POAG; E,
15		
16	8	PACG+POAG; F, VCDR.
17	9	
18 10	9	
19 20	10	
20 21	10	
21 22		
22		
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
37		
38 39		
40		
40		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51 52		
52 53		
53 54		
54 55		
55 56		
57		
58		
59		
60		21

BMJ Open by copyright, including for 70 Table 1 Baseline Characteristics of participants with POAG, PACG, PAC and PACS. n 70									
Normal, N		PAC		_ POAG, N (%					
(%)	PACS, N	PAC, N (%)		Total, N					
1153(100)	136 (100)	33 (100)	21 (đếg)	190 (100)	29 (100)				
			wnloa Supe text a						
440 (38.2)	17 (12.5)	5 (15.2)	nd dig 0 dig	22 (11.6)	4 (13.8)				
328 (28.5)	46 (33.8)	12 (36.4)	5 (23 28)	63 (33.2)	7 (24.1)				
385 (33.4)	73 (53.7)	16 (48.5)	16 (a 6.2)	105 (55.3)	18 (62.1)				
639 (55.4)	95 (69.9)	26 (78.8)	13 (E 1.	134 (70.5)	8 (27.6)				
809 (79.3)	93 (79.5)	19 (63.3)	12 (z 0.6)	124 (75.6)	22 (78.6)				
585 (72.7)	78 (82.1)	22 (88.0)	12 ()	112 (84.2)	19 (70.4)				
			m/ on						
716 (91.6)	79 (85.0)	16 (72.7)	11 (\$4.5)	106 (82.8)	23 (88.5)				
39 (4.99)	14 (15.1)	3 (13.6)	1 (269)	18 (14.1)	3 (11.5)				
27 (3.45)	0 (0)	3 (13.6)	1 (1 , 69)	4 (3.13)	0 (0)				
416 (40.1)	61 (45.9)	15 (45.5)	10 (50 🛱)	86 (46.2)	16 (57.1)				
105 (10.1)	16 (12.0)	3 (9.09)	4 (20.0)	23 (12.4)	3 (10.7)				
	(%) 1153(100) 440 (38.2) 328 (28.5) 385 (33.4) 639 (55.4) 809 (79.3) 585 (72.7) 716 (91.6) 39 (4.99) 27 (3.45) 416 (40.1)	(%)PACS, N1153(100)136 (100)440 (38.2)17 (12.5)328 (28.5)46 (33.8)385 (33.4)73 (53.7)639 (55.4)95 (69.9)809 (79.3)93 (79.5)585 (72.7)78 (82.1)716 (91.6)79 (85.0)39 (4.99)14 (15.1)27 (3.45)0 (0)416 (40.1)61 (45.9)	(%)PACS, NPAC, N (%)1153(100)136 (100)33 (100) $440 (38.2)$ 17 (12.5)5 (15.2)328 (28.5)46 (33.8)12 (36.4)385 (33.4)73 (53.7)16 (48.5)639 (55.4)95 (69.9)26 (78.8)809 (79.3)93 (79.5)19 (63.3)585 (72.7)78 (82.1)22 (88.0)716 (91.6)79 (85.0)16 (72.7)39 (4.99)14 (15.1)3 (13.6)27 (3.45)0 (0)3 (13.6)416 (40.1)61 (45.9)15 (45.5)	Normal, NPACDFree by PACS, NPAC, N (%)PAC PAC, N (%)PAC 	Normal, N (%)PACS, NPAC, N (%)PAGet (%)Total, N1153(100)136 (100)33 (100)21 (199) (100)190 (100)440 (38.2)17 (12.5)5 (15.2)022 (11.6)328 (28.5)46 (33.8)12 (36.4)5 (30.4)63 (33.2)385 (33.4)73 (53.7)16 (48.5)16 (76.2)105 (55.3)639 (55.4)95 (69.9)26 (78.8)13 (61.9)134 (70.5)809 (79.3)93 (79.5)19 (63.3)12 (75.6)124 (75.6)585 (72.7)78 (82.1)22 (88.0)12 (72.3)112 (84.2)716 (91.6)79 (85.0)16 (72.7)11 (76.6)18 (14.1)27 (3.45)0 (0)3 (13.6)1 (76.69)4 (3.13)416 (40.1)61 (45.9)15 (45.5)10 (50.4)86 (46.2)				

	45 (33.3) 535.5±33.4 15.1±2.88	12 (36.4) 542.9±29.8	njopen-zo zo-over, so ore by copyright, including 10 550.	0	
541.7±33.2 15.2±3.04 re disease, PO	535.5±33.4	542.9±29.8	10 (9 7.	ຊິ) 67 (35.5 ວ	
541.7±33.2 15.2±3.04 re disease, PO	535.5±33.4	542.9±29.8	<u>୧</u> ୦	0	
15.2±3.04 re disease, PO			550.4	0 2 0 538 4+32	
re disease, PO	15.1±2.88		935	j.0 000.4±02	2.5 542.5±35.2
		14.8±4.25	35 15 00 19.4≇ 8:2:2	36 15.5±3.7	71 15.8±2.87
ACS= Primary)AC=Primary or	pen angle glauc	oma, PAG	3= Primary angl	le closure
	angle closure s	suspect, BMI=Bo	ody mas	dex, PVI=Pres	enting visual
s, IOP=Intraocu	ular pressure		and d	рөµе,	
			r (AB ≸ata n	from	
			iES)	, http	
			g, Al	<i>U</i> hm	
			train		
			ing, a	3	
			ind si		
			imilar		
			. tech	line	
			inolo	د در د	
			gies.	005 c	
			-	+	
				lce	
	23			∽ Arar	
				hia	
			L. L.	-	
		Neer rev	Neer Eviewo	data mining, Al training, and similar technologies.	d from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Biblio. ur (ABES) - data mining, Al training, and similar technologies.

1	
י ר	
2	
2	
3 4 5 6 7 8	
5	
6	
7	
8	
9 10	
10	
11	
12	
12	
14	
14	
15	
16	
17	
12 13 14 15 16 17 18	
19	
20 21	
21	
22	
23	
24	
25	
25	
26 27	
27	
28	
29	
30	
31	
32	
33	
34	
25	
36	
37	
38	
39	
40	
41 42	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
55 54	
54 55	
56	
57	
58	
59	
60	


Table 2 Distribution of Basic Characters Associated with Mortality at Baseline Examination.


306 (100)	1066 (100)	
	1000 (100)	
		<0.001
23 (7.52)	443 (41.6)	
66 (21.6)	332 (31.1)	
217 (70.9)	291 (27.3)	
147 (48.0)	634 (59.5)	<0.001
155 (67.7)	800 (81.4)	<0.001
173 (83.2)	543 (71.7)	0.001
		0.009
169 (85.8)	676 (91.5)	
22 (11.2)	38 (5.14)	
6 (3.05)	25 (3.38)	
111 (44.4)	407 (40.6)	0.277
33 (13.2)	98 (9.79)	0.120
120 (39.5)	188 (17.6)	<0.001
0.49±0.18	0.44±0.17	<0.001
540.3±35.3	541.5±32.5	0.582
15.1±3.32	15.3±3.08	0.495
	66 (21.6) 217 (70.9) 147 (48.0) 155 (67.7) 173 (83.2) 169 (85.8) 22 (11.2) 6 (3.05) 111 (44.4) 33 (13.2) 120 (39.5) 0.49 ± 0.18 540.3 ± 35.3	$66 (21.6)$ $332 (31.1)$ $217 (70.9)$ $291 (27.3)$ $147 (48.0)$ $634 (59.5)$ $155 (67.7)$ $800 (81.4)$ $173 (83.2)$ $543 (71.7)$ $169 (85.8)$ $676 (91.5)$ $22 (11.2)$ $38 (5.14)$ $6 (3.05)$ $25 (3.38)$ $111 (44.4)$ $407 (40.6)$ $33 (13.2)$ $98 (9.79)$ $120 (39.5)$ $188 (17.6)$ 0.49 ± 0.18 0.44 ± 0.17 540.3 ± 35.3 541.5 ± 32.5

technologies. angle closure suspect, BMI=Body mass index, PVI=Presenting visual impairment, VCDR vertical cup-to-disc ratio, CCT=central cornea thickness, IOP=Intraocular pressure.

						BMJ Open		mjopen-2020-(d by copyright		F	age 26 of 31
1 2 3 4 5 6	1	Table 3 Cox	Proportional Haz	ards Mc	odels of ten-Year M	lortality Categorize	ed by Angl	040795 o , includir			
7 8			Participants,	Died,	Mortality Rate,			H)		
9 10 11			Ν	N	%(95%CI)	Univariable	P-value	Age and See Age	P-value	Multivariable	P-
11 12 13						Univaliable	i valuo		i valuo	Adjusted†	value
14	Angle Sta	atus						uperi xt and			
15 16	Normal		1153	235	20.4 (18.1,22.8)	Reference [1]		Refere		Reference [1]	
17 18	PAC		33	10	30.3 (15.6,48.7)	1.41(0.75,2.65)	0.284	1.27 (0. 2.39)	0.463	0.85 (0.37,1.94)	0.702
19 20	PACS		136	43	31.6 (23.9,40.1)	1.59(1.15,2.19)	0.005	1.32 (0.95, 583)	0.099	1.27 (0.84,1.90)	0.253
21 22	PACG		21	10	47.6 (25.7,70.2)	2.63(1.40,4.95)	0.003	2.15 (1. ﷺ 4, % 04)	0.018	1.60 (0.70,3.61)	0.263
23 24	PACD		190	63	33.2 (26.5,40.3)	1.74(1.32,2.30)	<0.001	1.46 (1.40)	0.009	1.25 (0.87,1.79)	0.221
25(26	PAC+PA POAG	CS+PACG)	29	8	27.6 (12.7,47.2)	1.31(0.65,2.65)	0.449	0.74 (0. 2 6, 1 49)	0.395	0.70 (0.32,1.51)	0.359
27 28	Any gla	ucoma	50	18	36.0 (22.9,50.8)	1.85(1.15,2.97)	0.012	1.18 (0. ² 3,1 <u>9</u> 91)	0.505	0.96 (0.54,1.71)	
29 30		+POAG)						echn			
31 32	2	Abbreviations	s: PAC= Primar	y angle	closure, PACS=	Primary angle clo	sure susp	pect, PACG Rimar	y angle cl	osure glaucoma,	
33 34	3	PACD=Prima	ary angle closure	disease	e, POAG=Primary o	open angle glauco	ma, HR=F	lazard ratio, C븙Conf	idence inte	rval.	
35 36	4	† Adjusted fo	r age, gender, e	ducation	, income, body ma	iss index, presenti	ng visual i	mpairment, history of	diabetes a	ind hypertension.	
37 38	5							Biblio			
39 40						25		3ibliographique			
41 42											
43 44				Fc	or peer review only - htt	p://bmjopen.bmj.com/s	ite/about/gu	uidelines.xhtml			
45 46											

ge 27 of 31				BMJ Open		mjopen-2020-040795 1 by copyright, inclu			
1 Table 4 Co	DX Proportional Participants,	Hazards Died,	Models of ten-Year Mortality	Mortality Categori	zed by IOF	u≓ o	CI)		
	Ν	N	Rate, %(95%CI)	Univariable	P-value	Age and Generation	P-value	Multivariable Adjusted†	P-value
IOP Unit increase	-	-	- Po	1.02(0.99,1.05)	0.580	1.02 (0.9931,000)	0.262	1.02 (0.99,1.05)	0.203
10~21 <10	1267 43	272 12	21.5(19.2,23.8) 27.9(15.3,43.7)	Reference [1] 1.32(0.74,2.35)	0.349	Reference (0.68,1:99)	0.680	Reference [1] 0.91 (0.44,1.89)	0.798
>21mmHg VCDR	50	14	28.0(16.2,42.5)	1.34(0.78,2.28)	0.291	0.97 (0.48 anii.997)	0.584	0.97 (0.49,1.91)	0.935
Unit increase <u><</u> 0.3	- 453	- 68	- 15.0(11.8,18.6)	3.86(2.05,7.26) Reference [1]	<0.001	1.76 (0.94 3.39) Reference [19]	0.076	1.59 (0.74,3.46) Reference [1]	0.238
>0.3	867	209	24.1(21.3,27.1)	1.71(1.30,2.25)	<0.001	1.53 (1.16 2.0)	0.002	1.60 (1.11,2.33)	0.011
		-	tion, income, body r		nting visual	ard ratio, CI goon of the second de impairment, his ory gence Bibliographique de guidelines.xhtml			1.





Page 30 of 31

Supplement Table 1 Cox Proportional Hazards Models of ten-Year Mortality Categorized by VaD R of different cu	.+ .ff
Subplement Table 1 Cox Proportional Hazards Models of ten-year Mortality Categorized by VigDre of different Ct	JL-OII.

	Participants,	Died,	Mortality Rate,						
	N	N	%(95%Cl)	Univariable	P-value	Age and ge onder Adjussed	P-value	Multivariable Adjusted†	P-value
VCDR			02			t Sup t ext			
<u><</u> 0.5	1012	197	19.5(17.1,22.0)	Reference [1]		Reference		Reference [1]	
>0.5	308	80	26.0(21.2,31.2)	1.37(1.06,1.78)	0.016	1.10 (0.54	0.500	1.11 (0.82,1.51)	0.490
VCDR						ining,			
<0.7	1160	229	19.7(17.5,22.2)	Reference [1]		Reference [1]		Reference [1]	
<u>></u> 0.7	160	48	30.0(23.0,37.7)	1.62(1.18,2.20)	0.003	1.16 (0,34,1.59)	0.367	1.15 (0.80,1.67)	0.445

d by copyright, includ mjopen-2020-040795

Abbreviations: IOP=Intraocular pressure, VCDR=Vertical cup disc ration, HR= Hazard ratio, CI=continuence interval.

t Adjusted for age, gender, education, income, body mass index, presenting visual impairment, this by of diabetes and hypertension تقريبي المحافة المح 13, 2025 at Agence Bibliographique de l

Page	31	of 31	
------	----	-------	--

		copyrigh	
		STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cobort studies	
Section/Topic	ltem #	Recommendation	Reported on page
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract ឆ្ក្រី ញុទ្ធិ	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3-4
Introduction		ated	
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported 6	6
Objectives	3	State specific objectives, including any prespecified hypotheses	7
Methods		and a serie	
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure,	7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifier Give diagnostic criteria, if	7-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-9
Bias	9	Describe any efforts to address potential sources of bias	7-9
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which goughness were chosen and why	8,10
Statistical methods	12	(<i>a</i>) Describe all statistical methods, including those used to control for confounding	10
		(b) Describe any methods used to examine subgroups and interactions	10
		(c) Explain how missing data were addressed	10
		(c) Explain how missing data were addressed Image: Comparison of the second s	
		(e) Describe any sensitivity analyses	

 mjopen-202 1 by copyrig

nique

del

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, exanyine for eligibility, confirmed	10-11
		eligible, included in the study, completing follow-up, and analysed ငို ဒို	
		(b) Give reasons for non-participation at each stage	11
		(c) Consider use of a flow diagram	11
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information of the social of	
		(b) Indicate number of participants with missing data for each variable of interest	10-11
		(c) Summarise follow-up time (eg, average and total amount)	11
Outcome data	15*	Report numbers of outcome events or summary measures over time	11
Main results	16	(<i>a</i>) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their preceding of the structure of the	11-12
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful dependent	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	12
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of applyses, results from similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	12-16
Other information		echn echn	
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, or the original study or which the present article is based		2	

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in case-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published exan bles of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.grg/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.spobe-statement.org.